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THERMO - KINETIC MIXING FOR mixing chamber and cooling the discharged batch to avoid 
PHARMACEUTICAL APPLICATIONS agglomeration of the resin particles . 
U . S . Pat . No . 5 , 895 , 790 issued to Good , is directed to 
CROSS - REFERENCE TO RELATED thermosetting a wide range of polymer blends . Briefly , a 
APPLICATIONS 5 wide range of polymer blends and waste thermoset material 
can be recovered . One method of thermosetting a wide range 
This application is a continuation of U . S . application Ser . polymer blends forms a homogenous and adaptable first 
No . 13 / 942 . 199 . filed Jul . 15 . 2013 , which is a divisional of method material . This material has a melt index of zero and 
U . S . application Ser . No . 12 / 196 . 154 . filed Aug . 21 . 2008 . a relatively predictable density . Very high levels of fibrous 
which claims priority to U . S . Provisional Application Ser . 10 non - polymers may be added to the first method material . 
No . 60 / 957 , 044 , filed Aug . 21 , 2007 , and U . S . Provisional U . S . Pat . No . 6 , 709 , 146 issued to Little , is directed to a 
Application Ser . No . 61 / 050 , 922 , filed May 6 , 2008 , the thermokinetic mixer and method of using . Briefly , a 
entire contents of each of which are incorporated herein by thermokinetic mixer has a mixing chamber with shaft pro 
reference . jections removable at least in part and replaceable without 15 cutting the projections from the shaft . In another embodi 
STATEMENT OF FEDERALLY FUNDED ment , only a tip portion of such projections are removable 
RESEARCH and replaceable without such cutting . In another embodi 
ment , shaft projections into the mixing chamber include a 
None . tooth having a substantially reticulated face forming a 
20 deflecting surface such that substantially all mixing chamber 
INCORPORATION - BY - REFERENCE OF particles encountering the tooth strike are deflected at an 
MATERIALS FILED ON COMPACT DISC incident substantially lateral angle from the deflecting sur 
face . 
None . 
SUMMARY OF THE INVENTION 
TECHNICAL FIELD OF THE INVENTION 
The present invention is directed to the application of the 
The present invention relates in general to the field of thermokinetic compounding ( TKC ) process in the field of 
pharmaceutical manufacturing , and more particularly , to pharmaceutical manufacturing , which offers numerous 
thermo - kinetic mixing of active pharmaceutical ingredients 30 advantages such as brief processing times , low processing 
( APIs ) to produce novel dosage forms . temperatures , high shear rates , and the ability to compound 
thermally incompatible materials into more homogenous 
BACKGROUND OF THE INVENTION composites . With these unique attributes , TKC offers a more 
efficient method of producing pharmaceutical compositions 
Current high - throughput molecular screening methods 35 than traditional pharmaceutical processing operations , and 
used by the pharmaceutical industry have resulted in a vast in some instances permits the production of compositions 
increase in the proportion of newly discovered molecular that can not be achieved by conventional methods . Thus , the 
entities which are poorly water - soluble ( 1 - 3 ) . The therapeu - application of TKC to pharmaceutical manufacturing repre 
tic potential of many of these molecules is often not fully sents a substantial advance in terms of processing efficiency , 
realized either because the molecule is abandoned during 40 compositional capabilities , as well as commercial viability 
development due to poor pharmacokinetic profiles , or of dosage forms of advanced formulation design , e . g . solid 
because of suboptimal product performance . Also , in recent dispersions . Moreover , TKC is an entirely novel process to 
years the pharmaceutical industry has begun to rely more pharmaceutical manufacturing . 
heavily on formulational methods for improving drug solu - An embodiment of the present disclosure is directed to a 
bility owing to practical limitations of salt formation and 45 method of making a pharmaceutical composition that 
chemical modifications of neutral or weakly acidic / basic includes one or more active pharmaceutical ingredients 
drugs ( 4 ) . Consequently , advanced formulation technologies ( API ) with one or more pharmaceutically acceptable excipi 
aimed at the enhancement of the dissolution properties of ents by thermokinetic compounding by thermokinetic pro 
poorly water - soluble drugs are becoming increasingly more cessing the one or more APIs with the one or more phar 
important to modern drug delivery . 50 maceutically acceptable excipients into a composite . The 
U . S . Pat . No . 4 , 789 , 597 issued to Gupta is directed to the novel pharmaceutical composition or composite made by 
incorporation of chemically reactive agents on resin par TKC may be further processed according to methods well 
ticles . Briefly , chemically reactive agents are locked to known to those of skill in the art , including but not limited 
particles of suitable synthetic resins without wholly fluxing to hot melt extrusion , melt granulation , compression mold 
the resins . A high quality intermediate product is obtained 55 ing , tablet compression , capsule filling , film - coating , or 
having no premature reaction taking place , suitable for injection molding into a final product . In certain embodi 
further techniques . The process includes the steps of inten - ments , the composite made by TKC is the final product . 
sively mixing and thermokinetically heating a batch of finely In one aspect , the composite is a homogenous , heterog 
divided resin particles , with a chemically reactive agent , in enous , or heterogeneously homogenous composite or an 
an enclosed mixing chamber with a plurality of blades 60 amorphous composite . In another aspect , the thermokinetic 
attached to arms rotating about a central axis within the processing may be conducted with or without a processing 
chamber , and having a blade tip speed of at least about 18 agent . Examples of processing agents include a plasticizer , 
meters per second , mixing the batch until the chemically a thermal lubricant , an organic solvent , an agent that facili 
reactive agent is locked to the resin particles , ensuring that tates melt blending , and an agent that facilitates downstream 
temperature of the batch stays well below decomposition 65 processing ( e . g . , lecithin ) . The thermokinetic processing 
temperature of the reactive agent and below fluxing tem - may be conducted in a thermokinetic chamber . A thermoki 
perature of the resin particles , discharging the batch from the netic chamber is an enclosed vessel or chamber in which 
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TKC occurs . In one aspect , the average temperature inside composites with less than about 1 . 0 % , 0 . 75 % , 0 . 5 % , 0 . 1 % , 
the chamber is ramped up to a pre - defined final temperature 0 . 05 % , or 0 . 01 % degradation products of each API . This 
over the duration of processing to achieve optimal thermoki advantage is important for thermally labile APIs , which 
netic mixing of the one or more APIs and the one or more typically undergo significant degradation during thermal 
pharmaceutically acceptable excipients into a composite . 5 processing , as well as APIs that are subject to oxidation . In 
The length of processing and exposure to elevated tempera - other embodiments , thermokinetic processing may generate 
tures during thermokinetic mixing will generally be below compositions with a minimum of at least about 90 % , 91 % , 
the thermal sensitivity threshold of the APIs , the excipients 92 % , 93 % , 94 % , 95 % , 96 % , 97 % , 98 % , 99 % , or 99 . 9 % drug 
or both . The composite may also include a carrier , e . g . , a potency with respect to each API . Examples of thermoki 
polymer with a high melt viscosity . In another aspect , the 10 netic processing may be performed for less than 5 , 10 , 15 , 
release rate profile of the one or more APIs is determined by 20 , 25 , 30 , 35 , 40 , 45 , 50 , 55 , 60 , 75 , 100 , 120 , 150 , 180 , 240 
the one or more excipients of the composition . As such , the and 300 seconds . Generally , thermokinetic processing may 
composition may be formulated for immediate release , be performed for between 5 and 120 seconds , 7 and 180 
mixed release , extended release or combinations thereof . seconds , 10 to 60 seconds , 15 to 45 seconds , and 20 to 30 
In another aspect , the particle size of the one or more APIs 15 seconds . In one aspect , the API has amorphous , crystalline , 
is reduced in an excipient / carrier system in which the APIs or intermediate morphology . 
are not miscible , not compatible , or not miscible or com - Another embodiment of the present invention includes a 
patible . In one aspect , the one or more APIs are a nanocom - method of processing a composite having one or more active 
posite with the excipient , a carrier , or the excipient and a pharmaceutical ingredients ( API ) with one or more pharma 
carrier . In another aspect , the thermokinetic processing is 20 ceutically acceptable excipients by thermokinetic com 
performed at an average temperature at or below the melting pounding , by thermokinetic processing the one or more APIs 
point of one or more of the APIs or excipients ; the thermoki - with the one or more pharmaceutically acceptable excipients 
netic processing is performed at an average temperature at or into a composite . Another embodiment of the present inven 
below the glass transition temperature of one or more of the tion includes a method of preprocessing a composite having 
APIs or excipients ; or the thermokinetic processing is per - 25 one or more active pharmaceutical ingredients ( API ) with 
formed at an average temperature at or below the molten one or more pharmaceutically acceptable excipients by 
transition point of one or more of the APIs or excipients . thermokinetic compounding , by thermokinetic processing 
In another aspect , the API may be a small organic the one or more APIs with the one or more pharmaceutically 
molecule , protein , peptide , or polynucleic acid . The aqueous acceptable excipients into a composite . The method may 
solubility of the API may be poorly soluble . Any pharma - 30 further include processing the composite by hot melt extru 
ceutically acceptable excipient known to those of skill in the sion , melt granulation , compression molding , tablet com 
art may be used to produce the composites and compositions pression , capsule filling , film - coating , or injection molding . 
disclosed herein . Examples of excipients for use with the In one aspect , the thermokinetic processing step does not 
present invention include , but are not limited to , e . g . , a include a processing agent . Examples of processing agents 
pharmaceutically acceptable polymer , a thermolabile poly - 35 include those selected from the group consisting of a plas 
meric excipient , or a non - polymeric exicipient . Other non - ticizer , a thermal lubricant , an organic solvent , an agent that 
limiting examples of excipients include , lactose , glucose , facilitates melt blending , and an agent that facilitates down 
starch , calcium carbonate , kaoline , crystalline cellulose , stream processing . The thermokinetic processing may be 
silicic acid , water , simple syrup , glucose solution , starch performed for less than 5 , 10 , 15 , 20 , 25 , 30 , 35 , 40 , 45 , 50 , 
solution , gelatin solution , carboxymethyl cellulose , shellac , 40 55 , 60 , 75 , 100 , 120 , 150 , 180 , 240 and 300 seconds , and any 
methyl cellulose , polyvinyl pyrrolidone , dried starch , ranges therein . 
sodium alginate , powdered agar , calcium carmelose , a mix - Yet another embodiment of the present invention includes 
ture of starch and lactose , sucrose , butter , hydrogenated oil , a method of preplasticizing one or more pharmaceutical 
a mixture of a quarternary ammonium base and sodium polymers by blending the polymers with one or more 
lauryl sulfate , glycerine and starch , lactose , bentonite , col - 45 plasticizer selected from the group consisting of oligomers , 
loidal silicic acid , talc , stearates , and polyethylene glycol , copolymers , oils , organic molecules , polyols having ali 
sorbitan esters , polyoxyethylene sorbitan fatty acid esters , phatic hydroxyls , ester - type plasticizers , glycol ethers , poly 
polyoxyethylene alkyl ethers , poloxamers ( polyethylene - propylene glycols ) , multi - block polymers , single block 
polypropylene glycol block copolymers ) , sucrose esters , polymers , poly ( ethylene oxides ) , phosphate esters ; phthalate 
sodium lauryl sulfate , oleic acid , lauric acid , vitamin E 50 esters , amides , mineral oils , fatty acids and esters thereof 
TPGS , polyoxyethylated glycolysed glycerides , dipalmitoyl with polyethylene glycol , glycerin or sugars , fatty alcohols 
phosphadityl choline , glycolic acid and salts , deoxycholic and ethers thereof with polyethylene glycol , glycerin or 
acid and salts , sodium fusidate , cyclodextrins , polyethylene sugars , and vegetable oils by thermokinetic mixing prior to 
glycols , polyglycolyzed glycerides , polyvinyl alcohols , agglomeration , by thermokinetic processing the one or more 
polyacrylates , polymethacrylates , polyvinylpyrrolidones , 55 polymers with the one or more plasticizers into a composite . 
phosphatidyl choline derivatives , cellulose derivatives , bio The method may further include the step of processing the 
compatible polymers selected from poly ( lactides ) , poly ( gly composite with one or more APIs by hot melt extrusion , melt 
colides ) , poly ( lactide - co - glycolides ) , poly ( lactic acid ) s , poly granulation , compression molding , tablet compression , cap 
( glycolic acid ) s , poly ( lactic acid - co - glycolic acid ) s and sule filling , film - coating , or injection molding . In one aspect , 
blends , combinations , and copolymers thereof . 60 the method may further include preplasticizing the polymers 
In another aspect , the method , compositions and compos - and plasticizers with one or more excipients . 
ite of the present invention may be adapted for oral , rectal , In yet another embodiment of the present invention , a 
vaginal , topical , urethral , otic , ocular , or transdermal admin method is used for dry milling one or more APIs by 
istration . In one advantage of the present disclosure , the thermokinetic compounding to reduce the particle size of the 
thermokinetic processing substantially eliminates API and 65 API bulk material . In certain aspects , the API is crystalline . 
excipient degradation . For example , in certain embodiments For example , by using this method , the particle size may be 
thermokinetic processing may generate compositions and reduced to less than 1000 um , 100 um , 10 um , or 1 um . As 
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lation 
described hereinabove , the thermokinetic mixing is per - 1 year , or 2 years when stored at , e . g . , ambient conditions or 
formed for less than 5 , 10 , 15 , 20 , 25 , 30 , 35 , 40 , 45 , 50 , 55 , the typical storage conditions for the API . 
60 , 75 , 100 , 120 , 150 , 180 , 240 and 300 seconds , and any The present invention is also directed to pharmaceutical 
ranges therein . compositions comprising one or more active pharmaceutical 
In a further modification of the present invention , com - 5 ingredients with one or more pharmaceutically acceptable 
binations of one or more APIs , one or more optional excipients wherein the composition is a homogenous , het 
functional excipients and one or more immiscible carrier erogenous , or heterogeneously homogenous composition in 
materials may be processed by thermokinetic mixing to which the glass transition temperature is significantly higher 
produce nanocomposites in situ . Processing may be con than the glass transition temperature of an identical formu 
ducted for times ranging from 5 to 1000 seconds at process - lation of identical active pharmaceutical ingredients and 
ing speeds and durations either above , at , or below the pharmaceutically acceptable excipients thermally processed , 
thermal transition temperature . Additional processing may with or without use of a plasticizer . In other embodiments , 
also be conducted to achieve a nanocomposites structure of the composition has a single glass transition temperature , 
the final product . Materials that may be used to generate 1 wherein the identical formulation thermally processed has 
nanocomposites include but are not limited to silica , talc , two or more glass transition temperatures . In still other 
magnesium stearate , colloidal silicon dioxide , clay , glycerol embodiments , the pharmaceutical compositions have a 
monstearate , steric acid , and the like . Physical properties of single glass transition temperature that is at least about 20 % , 
pharmaceutical compositions that may be modified using 30 % , 40 % , 50 % , 60 % , 70 % , 80 % , or 90 % higher than the 
thermokinetic mixing to achieve nanoconfinement are as 20 lowest glass transition temperature of the identical formu 
follows : lation thermally processed . The composition may be pro 
( a ) Pharmaceutical products with controlled drug release : cessed by thermokinetic compounding , and the identical 
The use of nanoconfinement may significantly increase formulation may be thermally processed according to meth 
the tortuosity of an API through dosage forms , e . g . , ods known to those of skill in the art , including but not 
controlled release dosage forms , by helping to control 25 limited to hot melt extrusion , melt granulation , compression 
the diffusion pathways and therefore drug release rates . molding , tablet compression , capsule filling , film - coating , or 
( b ) Pharmaceutical films with enhanced moisture trans injection molding . 
port properties : The use of nanoconfinement is con 
templated to regulate physical properties of the com BRIEF DESCRIPTION OF THE DRAWINGS 
position to help control moisture uptake , thereby 30 
producing compositions with more desirable process For a more complete understanding of the features and 
performance . advantages of the present invention , reference is now made 
( c ) Pharmaceutical Materials with enhanced downstream to the detailed description of the invention along with the 
processing characteristics : The use of nanoconfinement accompanying figures and in which : 
may provide enhanced mechanical properties , such as 35 FIG . 1 . HPLC analysis of ACM : EUDRAGIT® L 100 - 55 
changes to elastic moduli , to facilitate downstream ( 1 : 2 ) TKC processed material as compared to an ACM 
properties for tableting , encapsulation and other phar standard injection . 
maceutically acceptable dosage form development FIG . 2 . HPLC analysis of KTZ : Kollidon® 30 ( 1 : 2 ) TKC 
techniques known to those skilled in the art , e . g . , processed material in comparison to a KTZ standard injec 
injection molding , compression molding , film pressing , 40 tion and the Kollidon® 30 polymer alone . 
pelletizing , hot melt extrusion , melt granulation , tablet FIG . 3 . Modulated DSC analysis of : ( a ) MethocelTM E50 , 
compression , capsule filling , and film - coating . ( b ) amorphous KTZ , ( c ) TKC processed KTZ : MethocelTM 
( d ) Increased mechanical properties for pharmaceutical E50 ( 1 : 2 ) , and ( d ) HME processed KTZ : MethocelTM E50 
devices : The use of nanoconfinement may be able to ( 1 : 2 ) at 170° C . and 300 RPM . 
provide enhanced mechanical properties , for example 45 FIG . 4 . Modulated DSC analysis of : ( a ) Kollidon® 30 , ( b ) 
based on reduced relaxation events , particularly around amorphous KTZ , ( c ) TKC processed KTZ : Kollidon® 30 
physiological temperatures , which may allow the use of ( 1 : 2 ) , and ( d ) HME processed KTZ : Kollidon® 30 ( 1 : 2 ) at 
polymers that are not suitable for device applications 170° C . and 300 RPM . 
due to mechanical issues , ranging from transdermal FIG . 5 . Supersaturation dissolution testing of TKC pro 
patches to medicated dental floss to implantable 50 cessed KTZ : MethocelTM E50 and KTZ : Kollidon® 30 in 900 
devices , to be applied in these applications . These mL pH 6 . 8 phosphate buffer ( 37 + 0 . 2 ) by USP 29 Apparatus 
enhanced mechanical properties may also lead to a Il Method at 50 RPM . To each dissolution vessel ( n = 3 ) 300 
longer lifetime for such devices and therefore reduced mg of each composition ( 100 mg KTZ equivalent ) was 
dosing frequency . added resulting in a 111 ug / mL KTZ theoretical complete 
The present invention is also directed to the use of 55 dissolution concentration . This concentration is 18 . 6 times 
thermokinetic compounding , for example thermokinetic the equilibrium solubility of KTZ in neutral pH media ( 5 . 98 
mixing until melt blended , to produce a composite of two or ug / mL ) ( 42 ) . The standard deviation for the KTZ : Kollidon® 
more pharmaceutically acceptable excipients that are immis - ( 1 : 2 ) formulation is too slight to be viewed in the figure due 
cible by any other processing method known to those of skill to the magnitude of the C / Ce , scale . 
in the art . In one aspect , the composite is a heterogeneously 60 FIG . 6 . DSC analysis of the TKC processed KTZ : 
homogenous composite or an amorphous composite . EUDRAGIT® L 100 - 55 ( 1 : 4 ) and ( 1 : 2 ) . 
The present invention also includes a method of rendering FIG . 7 . DSC analysis of the TKC processed IND : 
a crystalline or semi - crystalline pharmaceutical polymer EUDRAGIT® L 100 - 55 ( 1 : 4 ) and ( 1 : 2 ) . 
amorphous for an extended duration by thermokinetic com - FIG . 8 . Dissolution analysis of griseofulvin : PVP K30 
pounding , for example thermokinetic mixing until melt 65 processed by TKC and by HME . 
blended . In one aspect of the present invention , the polymer FIG . 9 . PXRD analysis of griseofulvin : PVP K30 pro 
is rendered amorphous for greater than 2 months , 6 months , cessed by TKC and by HME . 
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FIG . 10 . DSC analysis of griseofulvin : PVP K30 pro temperature of an identical formulation of identical active 
cessed by TKC and by HME . pharmaceutical ingredients ( API ) and pharmaceutically 
FIG . 11 . Dissolution analysis of itraconazole : HPMC E5 acceptable excipients thermally processed , for example 
processed by TKC and by HME . either with or without the use of a plasticizer . The TKC 
FIG . 12 . PXRD analysis of itraconazole : HPMC E5 pro - 5 processing conditions can also produce a composition with 
cessed by TKC and by HME . a single glass transition temperature , wherein an identical 
FIG . 13 . DSC analysis of itraconazole : HPMC E5 pro formulation of identical active pharmaceutical ingredients 
cessed by TKC and by HME . and pharmaceutically acceptable excipients , processed ther 
FIG . 14 . Dissolution analysis of itraconazole : L100 - 55 mally , has two or more glass transition temperatures . In 
processed by TKC and by HME . 10 another example , the pharmaceutical compositions of the 
FIG . 15 . Calculation of precipitation rates of itraconazole : present disclosure have a single glass transition temperature 
L100 - 55 processed by TKC and HME . that is at least about 20 % , 30 % , 40 % , 50 % , 60 % , 70 % , 80 % , 
FIG . 16 . XRD analysis of itraconazole : L100 - 55 pro or 90 % higher than the lowest glass transition temperature of 
cessed by TKC . the identical formulation processed thermally . Alternatively , 
FIG . 17 . DSC analysis of itraconazole : L100 - 55 processed 15 the compositions made using thermokinetic processing may 
by TKC and by HME with added plasticizer ( TEC ) . generate compositions with a minimum of at least about 
FIG . 18 . mDSC heat flow profiles of Carbomer 974P , 90 % , 91 % , 92 % , 93 % , 94 % , 95 % , 96 % , 97 % , 98 % , 99 % , or 
itraconazole : L100 - 55 composites , and itraconazole : 99 . 9 % drug potency with respect to each API . 
Eudragit® L100 - 55 : Carbomer 974P composites , processed As used herein , the term " thermokinetic chamber ” refers 
by HME and TKC processed compositions . 20 to an enclosed vessel or chamber in which the TKC method 
FIG . 19 . mDSC reversing heat flow profiles are shown for is used to make the novel compositions of the present 
the composites of FIG . 18 . invention . In a TKC chamber the average temperature inside 
FIG . 20 . Heat flow profile of TKC processed composites the chamber is ramped up to a pre - defined final temperature 
containing Aerosil R972 compared to Aerosil R972 - free over the duration of processing to achieve thermokinetic 
composites . 25 compounding of the one or more APIs and the one or more 
FIG . 21 . Reversing heat flow profiles are shown for the pharmaceutically acceptable excipients into a composite . 
composites of FIG . 20 . The length of processing and exposure to elevated tempera 
tures during thermokinetic compounding will generally be 
DETAILED DESCRIPTION OF THE below the thermal sensitivity threshold of the APIs , the 
INVENTION 30 excipients or both . The pre - defined final temperature is 
selected to reduce the possibility that the one or more APIs , 
While the making and using of various embodiments of excipients and / or processing agents are degraded or their 
the present invention are discussed in detail below , it should functionality is impaired during processing . Generally , the 
be appreciated that the present invention provides many pre - defined final temperature , pressure , time of processing 
applicable inventive concepts that can be embodied in a 35 and other environmental conditions ( e . g . , pH , moisture , 
wide variety of specific contexts . The specific embodiments buffers , ionic strength , 0 , ) will be selected to substantially 
discussed herein are merely illustrative of specific ways to eliminate API , excipient and / or processing agent degrada 
make and use the invention and do not delimit the scope of tion . 
the invention . As used herein , “ bioavailability ” is a term meaning the 
To facilitate the understanding of this invention , a number 40 degree to which a drug becomes available to the target tissue 
of terms are defined below . Terms defined herein have after being administered to the body . Poor bioavailability is 
meanings as commonly understood by a person of ordinary a significant problem encountered in the development of 
skill in the areas relevant to the present invention . Terms pharmaceutical compositions , particularly those containing 
such as “ a ” , “ an ” and “ the ” are not intended to refer to only an active ingredient that is not highly soluble . In certain 
a singular entity , but include the general class of which a 45 embodiments such as formulations of proteins , the proteins 
specific example may be used for illustration . The terminol - may be water soluble , poorly soluble , not highly soluble , or 
ogy herein is used to describe specific embodiments of the not soluble . The skilled artisan will recognize that various 
invention , but their usage does not delimit the invention , methodologies may be used to increase the solubility of 
except as outlined in the claims . proteins , e . g . , use of different solvents , excipients , carriers , 
As used herein , the term “ thermokinetic compounding ” or 50 formation of fusion proteins , targeted manipulation of the 
“ TKC ” refers to a method of thermokinetic mixing until amino acid sequence , glycosylation , lipidation , degradation , 
melt blended . TKC may also be described as a thermokinetic combination with one or more salts and the addition of 
mixing process in which processing ends at a point some various salts . 
time prior to agglomeration . As used herein , the phrase " pharmaceutically acceptable ” 
As used herein , the phrase " a homogenous , heterogenous , 55 refers to molecular entities , compositions , materials , excipi 
or heterogeneously homogenous composite or an amor - ents , carriers , and the like that do not produce an allergic or 
phous composite ” refers to the various compositions that can similar untoward reaction when administered to humans in 
be made using the TKC method . general . 
As used herein , the term " heterogeneously homogeneous As used herein , “ pharmaceutically acceptable carrier ” or 
composite ” refers to a material composition having at least 60 " pharmaceutically acceptable materials ” includes any and 
two different materials that are evenly and uniformly dis - all solvents , dispersion media , coatings , antibacterial and 
tributed throughout the volume . antifungal agents , isotonic and absorption delaying agents , 
Whether the composition is a homogenous , heterogenous , and the like . The use of such media and agents for pharma 
or heterogeneously homogenous composition , an amor ceutical active substances is well known in the art . Except 
phous composition or combinations thereof , the TKC pro - 65 insofar as any conventional media or agent is incompatible 
cessing conditions can produce a composition with a glass with the active ingredient , its use in the pharmaceuticals 
transition temperature that is higher than the glass transition compositions and composites disclosed herein is contem 
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plated . Supplementary active ingredients can also be incor more chemical moieties on the parent molecule . Such moi 
porated into the compositions and composites . eties may include , but are not limited to , an element such as 
Examples of active pharmaceuticals ingredients ( APIs ) a hydrogen or a halide , or a molecular group such as a 
include , but are not limited to , antibiotics , analgesics , vac methyl group . Such a derivative may be prepared by any 
cines , anticonvulsants ; antidiabetic agents antifungal 5 method known to those of skill in the art . The properties of 
agents , antineoplastic agents , antiparkinsonian agents , anti such derivatives may be assayed for their desired properties rheumatic agents , appetite suppressants , biological response by any means known to those of skill in the art . As used modifiers , cardiovascular agents , central nervous system vous system herein , " analogs ” include structural equivalents or mimetics . stimulants , contraceptive agents , dietary supplements , vita A variety of administration routes are available for deliv mins , minerals , lipids , saccharides , metals , amino acids ( and 10 ering the APIs to a patient in need . The particular route precursors ) , nucleic acids and precursors , contrast agents , selected will depend upon the particular drug selected , the diagnostic agents , dopamine receptor agonists , erectile dys weight and age of the patient , and the dosage required for function agents , fertility agents , gastrointestinal agents , hor 
mones , immunomodulators , antihypercalcemia agents , mast therapeutic effect . The pharmaceutical compositions may 
cell stabilizers , muscle relaxants , nutritional agents , oph - 15 conveniently be presented in unit dosage form . The APIs 
thalmic agents , osteoporosis agents , psychotherapeutic suitable for use in accordance with the present disclosure , 
agents , parasympathomimetic agents , parasympatholytic and their pharmaceutically acceptable salts , derivatives , 
agents , respiratory agents , sedative hypnotic agents , skin analogs , prodrugs , and solvates thereof , can be administered 
and mucous membrane agents , smoking cessation agents , alone , but will generally be administered in admixture with 
steroids , sympatholytic agents , urinary tract agents , uterine 20 a suitable pharmaceutical excipient , diluent , or carrier 
relaxants , vaginal agents , vasodilator , anti - hypertensive , selected with regard to the intended route of administration 
hyperthyroids , anti - hyperthyroids , anti - asthmatics and ver - and standard pharmaceutical practice . 
tigo agents . In certain embodiments , the API is a poorly The APIs may be used in a variety of application modali 
water - soluble drug or a drug with a high melting point . ties , including oral delivery as tablets , capsules or suspen 
The API may be found in the form of one or more 25 sions ; pulmonary and nasal delivery ; topical delivery as 
pharmaceutically acceptable salts , esters , derivatives , ana - emulsions , ointments or creams ; transdermal delivery ; and 
logs , prodrugs , and solvates thereof . As used herein , a parenteral delivery as suspensions , microemulsions or 
" pharmaceutically acceptable salt ” is understood to mean a depot . As used herein , the term “ parenteral ” includes sub compound formed by the interaction of an acid and a base , cutaneous , intravenous , intramuscular , or infusion routes of 
the hydrogen atoms of the acid being replaced by the 30 administration . positive ion of the base . Non - limiting examples of pharma The solution agent used in the solution can be an aqueous ceutically acceptable salts include sulfate , citrate , acetate , such as water , one or more organic solvents , or a combina oxalate , chloride , bromide , iodide , nitrate , bisulfate , phos tion thereof . When used , the organic solvents can be water phate , acid phosphate , isonicotinate , lactate , salicylate , acid miscible or non - water miscible . Suitable organic solvents citrate , tartrate , oleate , tannate , pantothenate , bitartrate , 35 include but are not limited to ethanol , methanol , tetrahydro ascorbate , succinate , maleate , gentisinate , fumarate , glucon 
ate , glucaronate , saccharate , formate , benzoate , glutamate , furan , acetonitrile , acetone , tert - butyl alcohol , dimethyl sul 
methanesulfonate , ethanesulfonate , benzenesulfonate , foxide , N , N - dimethyl formamide , diethyl ether , methylene 
p - toluenesulfonate , and pamoate . Another method for defin - chloride , ethyl acetate , isopropyl acetate , butyl acetate , 
ing the ionic salts may be as an acidic functional group , such 40 propyl acetate , toluene , hexanes , heptane , pentane , and 
as a carboxylic acid functional group , and a pharmaceuti - combinations thereof . 
cally acceptable inorganic or organic base . Non - limiting The excipients and adjuvants that may be used in the 
examples of bases include , but are not limited to , hydroxides presently disclosed compositions and composites , while 
of alkali metals such as sodium , potassium and lithium ; potentially having some activity in their own right , for 
hydroxides of calcium and magnesium ; hydroxides of other 45 example , antioxidants , are generally defined for this appli 
metals , such as aluminum and zinc ; ammonia ; and organic cation as compounds that enhance the efficiency and / or 
amines , such as unsubstituted or hydroxy substituted mono - , efficacy of the effective ingredients . It is also possible to 
di - , or trialkylamines ; dicyclohexylamine ; tributylamine ; have more than one effective ingredient in a given solution , 
pyridine ; N - methyl - N - ethylamine ; diethylamine ; triethyl - so that the particles formed contain more than one effective 
amine ; mono - , bis - or tris - ( 2 - hydroxy - lower alkyl amines ) , 50 ingredient . 
such as mono - bis - or tris - ( 2 - hydroxyethyl ) amine , 2 - hy - As stated , excipients and adjuvants may be used to 
droxy - tert - butylamine , or tris - hydroxymethyl ) methylam - enhance the efficacy and efficiency of the APIs . Non - limiting 
ine , N , N - di - lower alkyl - N - ( hydroxy lower alkyl ) - amines , examples of compounds that can be included in the solutions 
such as N , N - dimethyl - N - ( 2 - hydroxyethyl ) amine , or tri - ( 2 are cryoprotectants , lyoprotectants , surfactants , fillers , sta 
hydroxyethyl ) amine ; N - methyl - D - glucamine ; and amino 55 bilizers , polymers , protease inhibitors , antioxidants and 
acids such as arginine , lysine , and the like . absorption enhancers . The excipients may be chosen to 
As used herein , " poorly soluble ” refers to having a modify the intended function of the effective ingredient by 
solubility such that the dose to be administered cannot be improving flow , or bioavailability , or to control or delay the 
dissolved in 250 ml of aqueous media ranging in pH from 1 release of the API . Specific nonlimiting examples include : 
to 7 . 5 , drugs with slow dissolution rates , and drugs with low 60 sucrose , trehaolose , Span 80 , Tween 80 , Brij 35 , Brij 98 , 
equilibrium solubilities , for example resulting in decreased Pluronic , sucroester 7 , sucroester 11 , sucroester 15 , sodium 
bioavailability or reduced pharmacological effect of the lauryl sulfate , oleic acid , laureth - 9 , laureth - 8 , lauric acid , 
therapeutic agent being delivered . vitamin E TPGS , Gelucire 50 / 13 , Gelucire 53 / 10 , Labrafil , 
As used herein , “ derivative ” refers to chemically modified dipalmitoyl phosphadityl choline , glycolic acid and salts , 
inhibitors or stimulators that still retain the desired effect or 65 deoxycholic acid and salts , sodium fusidate , cyclodextrins , 
property of the original API . Such derivatives may be polyethylene glycols , labrasol , polyvinyl alcohols , polyvinyl 
derived by the addition , removal , or substitution of one or pyrrolidones and tyloxapol . Using the process of the present 
POLYOX 
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invention , the morphology of the effective ingredients can be EA , 1 : 1 ) , Eudragit L - 100 - 55TM ( MA - EA , 1 : 1 ) , 
modified , resulting in highly porous microparticles and hydroxypropylmethylcellulose acetate succinate ( HPM 
nanoparticles . CAS ) , CoatericTM ( PVAP ) , AquatericTM ( CAP ) , and AQUA 
Exemplary thermal binders that may be used in the COATTM ( HPMCAS ) , polycaprolactone , starches , pectins ; 
presently disclosed compositions and composite include but 5 polysaccharides such as tragacanth , gum arabic , guar gum , 
are not limited to polyethylene oxide ; polypropylene oxide ; and xanthan gum . 
polyvinylpyrrolidone ; polyvinylpyrrolidone - co - vinylac The stabilizing and non - solubilizing carrier may also 
etate ; acrylate and methacrylate copolymers ; polyethylene ; contain various functional excipients , such as : hydrophilic 
polycaprolactone ; polyethylene - co - polypropylene ; alkylcel polymer , antioxidant , super - disintegrant , surfactant includ 
luloses such as methylcellulose ; hydroxyalkylcelluloses 10 ing amphiphilic molecules , wetting agent , stabilizing agent , 
such as hydroxymethylcellulose , hydroxyethylcellulose , retardant , similar functional excipient , or combination 
hydroxypropylcellulose , and hydroxybutylcellulose ; thereof , and plasticizers including citrate esters , polyethyl 
hydroxyalkyl alkylcelluloses such as hydroxyethyl methyl ene glycols , PG , triacetin , diethylphthalate , castor oil , and 
cellulose and hydroxypropyl methylcellulose ; starches , pec others known to those or ordinary skill in the art . Extruded tins ; polysaccharides such as tragacanth , gum arabic , guar material may also include an acidifying agent , adsorbent , gum , and xanthan gum . One embodiment of the binder is alkalizing agent , buffering agent , colorant , flavorant , sweet poly ( ethylene oxide ) ( PEO ) , which can be purchased com ening agent , diluent , opaquant , complexing agent , fragrance , mercially from companies such as the Dow Chemical Com preservative or a combination thereof . pany , which markets PEO under the POLY OXTM trademark 
exemplary grades of which can include WSR N80 having an 20 20 Exemplary hydrophilic polymers which can be a primary 
average molecular weight of about 200 , 000 ; 1 , 000 , 000 ; and or secondary polymeric carrier that can be included in the 
2 , 000 , 000 . composites or composition disclosed herein include poly 
Suitable grades of PEO can also be characterized by ( vinyl alcohol ) ( PVA ) , polyethylene - polypropylene glycol 
viscosity of solutions containing fixed concentrations of ( e . g . POLOXAMERTM ) , carbomer , polycarbophil , or chito 
PEO , such as for example : 25 san . Hydrophilic polymers for use with the present invention may also include one or more of hydroxypropyl methylcel 
lulose , carboxymethylcellulose , hydroxypropyl cellulose , 
Viscosity Range hydroxyethyl cellulose , methylcellulose , natural gums such 
Aqueous Solution as gum guar , gum acacia , gum tragacanth , or gum xanthan , 
Water - Soluble Resin NF at 25° C . , mPa . s 30 and povidone . Hydrophilic polymers also include polyeth 
ylene oxide , sodium carboxymethycellulose , hydroxyethyl POLYOX Water - Soluble Resin 30 - 50 ( 5 % solution ) methyl cellulose , hydroxymethyl cellulose , carboxypolym 
55 - 90 ( 5 % solution ) ethylene , polyethylene glycol , alginic acid , gelatin , polyvi 
NF WSR N - 80 nyl alcohol , polyvinylpyrrolidones , polyacrylamides , 
POLYOX Water - Soluble Resin 600 - 1 , 200 ( 5 % solution ) 35 polymethacrylamides , polyphosphazines , polyoxazolidines , NF WSR N - 750 
POLYOX Water - Soluble Resin 4 , 500 - 8 , 800 ( 5 % solution ) poly ( hydroxyalkylcarboxylic acids ) , carrageenate alginates , 
NF WSR - 205 carbomer , ammonium alginate , sodium alginate , or mixtures 
POLYOX Water - Soluble Resin 8 , 800 - 17 , 600 ( 5 % solution ) thereof . 
NF WSR - 1105 By “ immediate release ” is meant a release of an active POLYOX Water - Soluble Resin 400 - 800 ( 2 % solution ) 
NF WSR N - 12K 40 agent to an environment over a period of seconds to no more 
POLYOX Water - Soluble Resin 2 , 000 - 4 , 000 ( 2 % solution ) than about 30 minutes once release has begun and release 
NF WSR N - 60K begins within no more than about 2 minutes after adminis POLYOX Water - Soluble Resin 1 , 650 - 5 , 500 ( 1 % solution ) tration . An immediate release does not exhibit a significant NF WSR - 301 
POLYOX Water - Soluble Resin 5 , 500 - 7 , 500 ( 1 % solution ) delay in the release of drug . 
NF WSR Coagulant 45 By “ rapid release ” is meant a release of an active agent to 
POLYOX Water - Soluble Resin 7 , 500 - 10 , 000 ( 1 % solution ) an environment over a period of 1 - 59 minutes or 0 . 1 minute NF WSR - 303 to three hours once release has begun and release can begin 
within a few minutes after administration or after expiration 
Suitable thermal binders that may or may not require a of a delay period ( lag time ) after administration . 
plasticizer include , for example , EudragitTM RS PO , 50 As used herein , the term " extended release ” profile 
EudragitTM S100 , Kollidon SR ( poly ( vinyl acetate ) - co - poly assumes the definition as widely recognized in the art of 
( vinylpyrrolidone ) copolymer ) , EthocelTM ( ethylcellulose ) , pharmaceutical sciences . An extended release dosage form 
HPC ( hydroxypropylcellulose ) , cellulose acetate butyrate , will release the drug ( i . e . , the active agent or API ) at a 
poly ( vinylpyrrolidone ) ( PVP ) , poly ( ethylene glycol ) ( PEG ) , substantially constant rate over an extended period of time 
poly ( ethylene oxide ) ( PEO ) , poly ( vinyl alcohol ) ( PVA ) , 55 or a substantially constant amount of drug will be released 
hydroxypropyl methylcellulose ( HPMC ) , ethylcellulose incrementally over an extended period of time . An extended 
( EC ) , hydroxyethylcellulose ( HEC ) , sodium carboxym - release tablet generally effects at least a two - fold reduction 
ethyl - cellulose ( CMC ) , dimethylaminoethyl methacrylate in dosing frequency as compared to the drug presented in a 
methacrylic acid ester copolymer , ethylacrylate - methyl - conventional dosage form ( e . g . , a solution or rapid releasing 
methacrylate copolymer ( GA - MMA ) , C - 5 or 60 SH - 50 60 conventional solid dosage forms ) . 
( Shin - Etsu Chemical Corp . ) , cellulose acetate phthalate By " controlled release ” is meant a release of an active 
( CAP ) , cellulose acetate trimelletate ( CAT ) , poly ( vinyl agent to an environment over a period of about eight hours 
acetate ) phthalate ( PVAP ) , hydroxypropylmethylcellulose up to about 12 hours , 16 hours , 18 hours , 20 hours , a day , or 
phthalate ( HPMCP ) , poly ( methacrylate ethylacrylate ) ( 1 : 1 ) more than a day . By “ sustained release ” is meant an 
copolymer ( MA - EA ) , poly ( methacrylate methylmethacry - 65 extended release of an active agent to maintain a constant 
late ) ( 1 : 1 ) copolymer ( MA - MMA ) , poly ( methacrylate meth drug level in the blood or target tissue of a subject to which 
ylmethacrylate ) ( 1 : 2 ) copolymer , Eudragit L - 30 - DTM ( MA the device is administered . 
NF WSR N - 10 
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The term " controlled release ” , as regards to drug release , release profile of the first tablet is determined after the single 
includes the terms “ extended release ” , “ prolonged release ” , day of storage and the release profile of the second tablet is 
“ sustained release " , or " slow release ” , as these terms are determined after the four months of storage . If the release 
used in the pharmaceutical sciences . A controlled release can profile of the first tablet is approximately the same as the 
begin within a few minutes after administration or after 5 release profile of the second tablet , then the tablet / film 
expiration of a delay period ( lag time ) after administration . formulation is considered to have a stable release profile . 
A slow release dosage form is one that provides a slow Another example of a composition or formulation having 
rate of release of drug so that drug is released slowly and a stable release profile follows . Tablets A and B , each approximately continuously over a period of 3 hr , 6 hr , 12 hr , comprising a composition according to the invention , are 18 hr , a day , 2 or more days , a week , or 2 or more weeks , 10 made , and Tablets C and D , each comprising a composition for example . not according to the invention , are made . Tablets A and Care The term “ mixed release " as used herein refers to a each stored for one day under a first set of conditions , and pharmaceutical agent that includes two or more release 
profiles for one or more active pharmaceutical ingredients . tablets B and D are each stored for three months under the 
For example , the mixed release may include an immediate 15 same first set of conditions . The release profile for each of 
release and an extended release portion , each of which may tablets A and C is determined after the single day of storage 
be the same API or each may be a different API . and designated release profiles A and C , respectively . The 
A timed release dosage form is one that begins to release release profile for each of tablet B and D is determined after 
drug after a predetermined period of time as measured from the three months of storage and designated release profiles 
the moment of initial exposure to the environment of use . 20 B and D , respectively . The differences between release 
A targeted release dosage form generally refers to an oral profiles A and B are quantified as are the differences between 
dosage form that is designed to deliver drug to a particular release profiles C and D . If the difference between the 
portion of the gastrointestinal tract of a subject . An exem - release profiles A and B is less than the difference between 
plary targeted dosage form is an enteric dosage form that release profiles C and D , tablets A and B are understood to 
delivers a drug into the middle to lower intestinal tract but 25 provide a stable or more stable release profile . 
not into the stomach or mouth of the subject . Other targeted Specifically , the TKC process can be used for one or more 
dosage forms can deliver to other sections of the gastroin - of the following pharmaceutical applications . 
testinal tract such as the stomach , jejunum , ileum , duode - Dispersion of one or more APIs , wherein the API is a 
num , cecum , large intestine , small intestine , colon , or rec - small organic molecule , protein , peptide , or polynucleic 
tum . 30 acid ; in polymeric and / or non - polymeric pharmaceutically 
By " delayed release ” is meant that initial release of drug acceptable materials for the purpose of delivering the API to 
occurs after expiration of an approximate delay ( or lag ) a patient via oral , pulmonary , parenteral , vaginal , rectal , 
period . For example , if release of drug from an extended urethral , transdermal , or topical routes of delivery . 
release composition is delayed two hours , then release of the Dispersion of one or more APIs , wherein the API is a 
drug begins at about two hours after administration of the 35 small organic molecule , protein , peptide , or polynucleic 
composition , or dosage form , to a subject . In general , a acid ; in polymeric and / or non - polymeric pharmaceutically 
delayed release is opposite of an immediate release , wherein acceptable materials for the purpose of improving the oral 
release of drug begins after no more than a few minutes after delivery of the API by improving the bioavailability of the 
administration . Accordingly , the drug release profile from a API , extending the release of the API , targeting the release 
particular composition can be a delayed - extended release or 40 of the API to specific sites of the gastrointestinal tract , 
a delayed - rapid release . A " delayed - extended ” release pro - delaying the release of the API , or producing pulsatile 
file is one wherein extended release of drug begins after release systems for the API . 
expiration of an initial delay period . A " delayed - rapid ” Dispersion of one or more APIs , wherein the API is a 
release profile is one wherein rapid release of drug begins small organic molecule , protein , peptide , or polynucleic 
after expiration of an initial delay period . 45 acid ; in polymeric and / or non - polymeric pharmaceutically 
Apulsatile release dosage form is one that provides pulses acceptable materials for the purpose of creating bioerodible , 
of high active ingredient concentration , interspersed with biodegradable , or controlled release implant delivery 
low concentration troughs . A pulsatile profile containing two devices . 
peaks may be described as “ bimodal . ” A pulsatile profile of Producing solid dispersions of thermolabile APIs by pro 
more than two peaks may be described as multi - modal . 50 cessing at low temperatures for very brief durations . 
A pseudo - first order release profile is one that approxi - Producing solid dispersions of APIs in thermolabile poly 
mates a first order release profile . A first order release profile mers and excipients by processing at low temperatures for 
characterizes the release profile of a dosage form that very brief durations . 
releases a constant percentage of an initial drug charge per Rendering a small organic API amorphous while dispers 
unit time . 55 ing in a polymeric , non - polymeric , or combination excipient 
A pseudo - zero order release profile is one that approxi - carrier system . 
mates a zero - order release profile . A zero - order release Dry milling of crystalline API to reduce the particle size 
profile characterizes the release profile of a dosage form that of the bulk material . 
releases a constant amount of drug per unit time . Wet milling of crystalline API with a pharmaceutically 
The resulting composites or compositions disclosed 60 acceptable solvent to reduce the particle size of the bulk 
herein may also be formulated to exhibit enhanced dissolu - material . 
tion rate of a formulated poorly water soluble drug . Melt milling of a crystalline API with one or more molten 
An example of a composition or formulation having a pharmaceutical excipients having limited miscibility with 
stable release profile follows . Two tablets having the same the crystalline API to reduce the particle size of the bulk 
formulation are made . The first tablet is stored for one day 65 material . 
under a first set of conditions , and the second tablet is stored Milling crystalline API in the presence of polymeric or 
for four months under the same first set of conditions . The non - polymeric excipient to create ordered mixtures where 
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fine drug particles adhere to the surface of excipient particles phous compositions of high melting point actives ( KTZ and 
and / or excipient particles adhere to the surface of fine drug IND ) in the thermolabile polymer EUDRAGIT® L 100 - 55 
particles . were produced by TKC processing without the addition of 
Producing heterogeneously homogenous composites or processing aids . The results of this study establish TKC as 
amorphous composites of two or more pharmaceutical 5 a novel technology for producing amorphous pharmaceuti 
excipients for post - processing , e . g . , milling and sieving , cal solid dispersion systems . The unique attributes of TKC 
which are subsequently utilized in secondary pharmaceuti were shown to provide expanded manufacturing capabili 
cal operations well known to those of skill in the art , e . g . , well known to those of skill in the art , e . g . , ties , which present innovative formulation opportunities for 
film coating , tableting , wet granulation and dry granulation , amorphous solid dispersion systems . 
roller compaction , hot melt extrusion , melt granulation , 10 Examination of the Noyes - Whitney equation ( Equation 1 ) E compression molding , capsule filling , and injection molding . ng . ( 5 ) for the rate of solids dissolution reveals the method by Producing single phase , miscible composites of two or which the dissolution properties of poorly water - soluble more pharmaceutical materials previously considered to be 
immiscible for utilization in a secondary processing step , drug particles can be enhanced with formulation : 
e . g . melt extrusion , film coating , tableting and granulation . 15 
Pre - plasticizing polymeric materials for subsequent use in 
film coating or melt extrusion operations . dC ( 1 ) DA ( Cs – C ; ) dth Rendering a crystalline or semi -crystalline pharmaceuti 
cal polymer amorphous , which can be used as a carrier for 
an API in which the amorphous character improves the 20 dC / dt - Rate of solute dissolution 
dissolution rate of the API - polymer composite , the stability D Diffusion coefficient 
of the API - polymer composite , and / or the miscibility of the A - Effective surface area 
API and the polymer . C , Saturation concentration 
Deaggregate and disperse engineered particles in a poly C . – Drug concentration at time t 
meric carrier without altering the properties of the engi - 25 h - Width of stagnant diffusion layer 
neered particles . The total solute surface area ( theoretical drug surface 
Simple blending of an API in powder form with one or area ) is increased via formulational methods by reducing 
more pharmaceutical excipients . drug particle size . An increase in total solute area may be 
Producing composites comprising one or more high melt accomplished by one of various techniques ranging from dry 
ing point APIs and one or more thermolabile polymers 30 milling of drug crystals to the formation of solid solutions of 
without the use of processing agents . drugs in excipient carriers . The formation of a solid solution 
Homogenously dispersing a coloring agent or opacifying represents the limit of particle size reduction as drug par 
agent within a polymer carrier or excipient blend . ticles are divided and dispersed as individual molecules . 
Increasing the effective surface area , that portion of the total 
Example 1 surface area which is in intimate contact with the solvent , is 
achieved with formulation by encapsulating drug particles / 
This study investigates the application of a novel manu molecules in hydrophilic excipients . Hydrophilic encapsu 
facturing process , thermokinetic compounding ( TKC ) , to lation reduces the surface tension between the aqueous 
the production of amorphous solid dispersion systems . The medium and the hydrophobic drug particles , thereby 
TKC process offers many of the same attributes that have 40 improving wettability and increasing the solvent surface 
made hot - melt extrusion ( HME ) a preferred method of coverage of the drug solute ( 6 ) . Additionally , encapsulating 
manufacture for solid dispersions formulations . However , particles in hydrophilic excipients decreases hydrophobic 
TKC has some very unique capabilities that distinguish the interactions between drug particles in aqueous media and 
process from HME and suggest vast potential for innovative thus reduces aggregation . It is seen from Equation 1 that the 
applications to various facets of pharmaceutical manufac - 45 overall result of increasing the effective surface area ( A ) is 
turing . Specifically , TKC offers the benefits of very brief a proportionate increase in the dissolution rate ( dC / dt ) of 
processing times , low processing temperatures , molten mix - drug particles . 
ing without viscous flow , and significantly higher rates of Altering the morphology of drug particles from the most 
shear than typical twin - screw melt extruders . It was the aim thermodynamically stable crystalline form to a higher 
of this study to investigate the use of TKC for the production 50 energy conformation ( polymorph ) accelerates dissolution by 
of amorphous pharmaceutical solid dispersion systems to increasing the apparent saturation concentration ( Cs ) of the 
assess its potential as an alternative technology to HME . drug in the aqueous medium . Relating back to Equation 1 , 
Various solid dispersion systems were produced by TKC a greater C , value increases the solution saturation concen 
with different model drugs ( acetaminophen ( ACM ) , keto - tration gradient ( Cs - Ct ) , thus providing a larger driving 
conazole ( KTZ ) and indomethacin ( IND ) ) and different 55 force for dissolution . Polymeric carriers in amorphous drug 
polymeric carriers ( MethocelTM E50 , Kollidon® 30 , and formulations can provide a stabilizing effect on supersatu 
EUDRAGIT® L 100 - 55 ) . Chromatographic analysis of rated ITZ solutions , hence further increasing the apparent 
solid dispersions of ACM and KTZ revealed no apparent drug solubility and concurrently the overall dissolution rate . 
degradation of these active agents by TKC processing . The utilization of polymers as stabilizers of supersaturated 
Differential scanning calorimetry ( DSC ) revealed that amor - 60 solutions is thus another method of improving the dissolu 
phous composites of KTZ in both MethocelTM E50 and tion properties of poorly water - soluble drug molecules . 
Kollidon® 30 were achieved by TKC processing and these Solid dispersion technologies are widely used formula 
compositions had similar attributes to the same formulations tional techniques for improving the solubility characteristics 
processed by HME . Dissolution studies demonstrated exten - of poorly water - soluble drugs . Each of the aforementioned 
sive KTZ supersaturation in pH 6 . 8 phosphate buffer from 65 modes of improving the dissolution properties of poorly 
an amorphous dispersion of KTZ in MethocelTM E50 ( 1 : 2 ) soluble drug substances can be achieved simultaneously in 
produced by TKC . DSC revealed that substantially amor the production of a solid dispersion formulation . For drug 
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substances that are extremely insoluble , amorphous solid populations and in turn signify the emergence of HME as a 
dispersion systems are often the only option for markedly viable commercial manufacturing process for the production 
improving dissolution rate owing to the thermodynamic of solid dispersion formulations . 
stability of the crystal lattice structure ( 7 ) . Numerous meth Although HME may be one of the most viable methods of 
ods for the production of solid dispersions have been 5 producing solid dispersion formulations , the process is not 
reported in the scientific literature ; however , all of these without a few critical limitations . Firstly , thermal incompat 
methods are variations on either solvent or thermal treatment ibility of drug substances and carrier excipients is a common 
methods . Solvent techniques include such common pro problem encountered with HME processing of pharmaceu 
cesses as solvent evaporation ( 8 ) , co - precipitation ( 9 , 10 ) , tical formulations ( 14 ) . What is meant by thermal incom 
and spray drying ( 11 ) , but also include more recently dem - 10 patibility in this case is that the onset of thermal degradation 
onstrated techniques like cryogenic and supercritical fluid of one of the formulation components is below the molten 
technologies ( 12 , 13 ) . Although the process details of these transition ; i . e . glass transition temperature ( T ) or melting 
methods are quite different , the starting point is identical : the point ( Tn ) , of another component . When amorphous com 
drug and the stabilizing excipients must be dissolved in a positions of ITZ in EUDRAGIT® L 100 - 55 and HP - 55 were 
common solvent system . The end point of each of the 15 desired , the onset of degradation of these polymers was 
processes is also identical : the solids must be recovered via below the melting point of the drug and too near to the T S 
solvent removal . These two commonalties are significant to process them by HME without the use of formulation 
disadvantages of solvent - based solid dispersion processes . additives . The inverse of this example , where the onset of 
The use of solvents is costly , toxic to humans and the degradation of the drug substance occurs below the Tms or 
environment , and the requirement of common solubility of 20 Tos of the desired carrier excipients , is also a considerable 
the drug and the excipients in the solvent system can be very obstacle to the utilization of HME in pharmaceutical manu 
restrictive with respect the excipients which can be used in facturing ( 36 ) . When these thermal degradation issues are 
the formulation ( 4 , 14 , 15 ) . Additionally , solvent removal encountered , the most common solution is to reduce pro 
can be a lengthy process which reduces manufacturing cessing temperatures by lowering the temperature at which 
efficiency . It is for these reasons that thermal methods of 25 the molten transition of the carrier excipient ( s ) occurs . This 
producing solid dispersion systems are preferred over sol - is accomplished by the addition of plasticizing additives to 
vent methods . the formulation . In another example , 20 % triethyl citrate 
Early batch thermal methods involved heating the active ( TEC ) was incorporated into the EUDRAGIT® L 100 - 55 , 
and the carrier excipients in a vessel under agitation to a HP - 55 , and EUDRAGIT® L 100 - 55 / Carbopol 974P carrier 
point where either the drug or the stabilizing excipient ( s ) or 30 systems to enable HME processing below the temperature at 
both were rendered molten ( 16 - 20 ) . Owing to mixing and which thermal degradation of these polymers begins . In 
heating inefficiencies as well as prolonged heat exposure of cases where thermal degradation is not a problem , plasti 
the product , these early batch processes were not viable cizers or thermal lubricants may still be required in order to 
methods of producing solid dispersion systems on a large reduce the melt viscosity of carrier excipients to facilitate 
scale . With the application of hot - melt extrusion ( HME ) to 35 molten flow of the formulation inside the extruder barrel . 
the production of solid dispersion systems , problems of Particularly with high molecular weight polymers , the melt 
heating and mixing inefficiencies were remedied and the viscosity generates excessive load on the drive motor and 
continuous nature of the process also improved the manu - precludes processing without the incorporation of additives 
facturing efficiency ( 14 , 21 ) . to facilitate molten flow . 
Numerous reports have been published in the pharmaceu - 40 The importance of the glass transition temperature for 
tical literature on the use of HME for the production of solid long term stability of pharmaceutical solids is well known . 
dispersion systems not only for the improvement of the Amorphous compositions have been well documented in the 
dissolution properties of poorly water - soluble compounds , literature for the improved dissolution rates achieved in vitro 
but also for the production of sustained release matrix and the enhanced bioavailabilities attained in vivo , however 
systems ( 22 - 33 ) . Although reports in the pharmaceutical 45 these compositions are thermodynamically unstable and the 
literature and patents claiming the use of HME for pharma - glass transition temperature has been indicated as a predictor 
ceutical applications date back several decades , the com - of the solid state stability that can be attained for a compo 
mercial use of HME has been limited ( 4 , 15 ) . However , in sition . As a result of the thermodynamic instability of the 
recent years the utilization of HME for the production of system , these compositions will transition to the crystalline 
commercial solid dispersion systems appears to be increas - 50 state over a given period of time , with the length of time 
ing . For example , Soliqs , a subsidiary of Abbott GmbH and dependent on the molecular mobility within the system . As 
Co . KG , is actively marketing a platform , HME - based drug the composition storage temperature increases , approaching 
delivery technology known as MeltrexTM The MeltrexTM the glass transition temperature , molecular mobility 
system is the underlying technology utilized in the produc increases therefore it is recommended to develop composi 
tion of the new Kaletra® ( lopinavir / ritonavir ) tablet that 55 tions with a substantially higher glass transition temperature 
replaced the former soft gelatin capsule formulation by than the storage condition temperature to prevent recrystal 
providing a simpler more convenient anti - HIV drug therapy lization ( 15 ) . Although plasticizers improve processing dur 
( 34 ) . The widely prescribed contraceptive NuvaRing® is ing melt extrusion , they also substantially lower the glass 
another example of a recently commercialized solid disper - transition temperature which can reduce solid state stability 
sion formulation produced by HME . NuvaRing® is a sus - 60 of amorphous compositions . Production using TKC without 
tained release etonogestrel / ethinyl estradiol ring - shaped the aid of the plasticizer results in compositions with sub 
vaginal insert which is rapidly growing in popularity due to stantially higher glass transition temperatures which can 
its far more convenient dosing schedule over the more provide enhanced solid state stability . 
traditional tablet contraceptives . The 2006 U . S . sales for The present inventors recognized that a problem associ 
Kaltera® and NuvaRing® were 360 and 170 million ( USD ) , 65 ated with plasticization of polymeric carriers is in regard to 
respectively ( 35 ) . These sales figures demonstrate the amorphous solid dispersion systems and the reduction of the 
impact these products are having on their respective patient composite Tg . The addition of plasticizer to polymeric 
19 
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carriers reduces the To of the matrix and promotes molecular ing such as high shear rates , brief processing times that limit 
mobility of the carrier and consequently recrystallization of heat exposure of processing materials to just a few seconds , 
amorphous drug dispersed within ( 37 ) . The ultimate result is as well as the ability to process materials in their molten 
a dynamic drug release profile of the product on storage . state at temperatures below their typical molten transitions . 
Drug release which varies with storage time diminishes the 5 Processing molten polymers below their molten transition 
safety and efficacy of drug products and therefore would temperatures may enable the production of solid dispersion 
preclude the marketability of formulations that lead to such systems from thermally incompatible materials . As molten 
instability . flow does not occur during TKC processing , processing 
These limitations of HME processing of pharmaceutical additives such as plasticizers and thermal lubricants may not 
solid dispersion systems prompted the current study in 10 be necessary , which is another advantage over other manu 
which a novel process , thermokinetic compounding ( TKC ) , facturing processes known in the art . 
was evaluated as a method of producing pharmaceutical Based on the present findings , TKC processing has sub 
solid dispersion systems . TKC is a derivative of thermoki - stantial applications to pharmaceutical manufacturing . The 
netic mixing ( TKM ) which is an established , yet little known TKC process was used to produce amorphous solid disper 
process in the polymer industry . It is used for blending 15 sion formulations of poorly water - soluble drugs in various 
additives like colorants , cellulose , graphite , clays , chemical polymeric carriers , since it is believed that the attributes of 
agents ( like foaming agents or fire retardants ) and rubbers the TKC apply particularly well to this aspect of pharma 
into polymers ( 38 - 40 ) . The process is flexible and can blend ceutical manufacturing . Firstly , as demonstrated herein , 
materials with or without agglomeration ( rendering the TKC is able to achieve the same result as melt extrusion with 
polymer molten ) with varying degrees of effect . This flex - 20 respect to producing amorphous solid dispersion systems of 
ibility is particularly useful when dispersing additives within ketoconazole ( KTZ ) with thermally stable polymers . Sec 
heat sensitive polymers where thermal degradation is a ondly , as demonstrated herein , TKC offers certain advan 
significant issue . This flexibility is the primary advantage tages over HME by producing amorphous solid dispersions 
over its main competitive process , twin - screw extrusion of high melting point drugs in the thermolabile 
compounding , which requires melting of the polymer . In 25 EUDRAGIT® L 100 - 55 polymer without the addition of 
cases where TKM is used for agglomeration , it has another plasticizers or other processing aids . 
advantage over twin - screw extrusion in that the materials are Materials and Methods . Ketoconazole , USP ( KTZ ) was 
exposed to heat for much shorter durations . Additionally , purchased from Hawkins , Inc . ( Minneapolis , Minn . ) . Acet 
TKM has been estimated to produce rates of shear much aminophen , USP ( ACM ) was purchased from Fisher Scien 
greater than twin - screw extrusion ( 39 ) . When agglomeration 30 tific Co . ( Houston , Tex . ) . Indomethacin , USP ( IND ) was 
is necessary , TKM has higher processing costs than twin purchased from Spectrum Chemical Mfg . Corp . ( Gardena , 
screw extrusion , so the polymer industry only uses it in very Calif . ) . Kollidon® 30 PF ( Povidone K 30 USP ) was pro 
limited applications . vided by BASF , ( Ludwigshafen , Germany ) . MethocelTM 
TKC is a unique , proprietary variation of TKM . The term E50 Premium LV ( Hydroxypropyl methylcellulose 2910 50 
thermokinetic compounding as used herein refers to 35 cPs ) were provided by The Dow Chemical Company , ( Mid 
thermokinetic mixing used for melt blending . TKS also land , Mich . ) . EUDRAGIT® L 100 - 55 was purchased from 
refers to thermokinetic mixing which is stopped prior to Degussa GmbH ( Linden , N . J . ) . HPLC grade Acetonitrile 
agglomeration . One novel composition and method of the was purchased from EMD chemicals ( Darmstadt , Ger 
present disclosure is to change from a heat sensitive process many ) . All other chemicals used in this study were of ACS 
to an aggressive heat intensive process focusing on agglom - 40 grade . 
eration . The result of this novel process is that it compati - Thermokinetic Compounding . One example of a 
bilizes vastly different polymers , e . g . , thermoset ( non - melt - thermokinetic compounder has a high horsepower motor 
ing ) polymers with thermoplastic ( melting ) polymers , as driving the rotation of a horizontal shaft with teeth - like 
well as crystalline thermoplastics with highly amorphous protrusions that extend outward normal to the rotational axis 
thermoplastics . These compositions are not simply mixed by 45 of the shaft . The portion of the shaft containing the protru 
this process , but rather the two materials become bonded . sions is contained within an enclosed vessel where the 
Additionally , polymers with vastly different melting tem compounding operation takes place , i . e . , a thermokinetic 
peratures are able to be processed together without degrad - chamber . The high rotational velocity of the shaft coupled 
ing the more heat - sensitive polymer . TKC processing times with the design of the shaft protrusions imparts kinetic 
are brief ( e . g . , less than a minute ) to minimize the heat 50 energy onto the materials being processed . Each processed 
exposure of compounded materials ( active and / or non - ac - batch contained the API and the polymer in a 1 : 2 ( w / w ) ratio 
tive ) . With TKC , polymeric materials are rendered molten with a total batch size of 1 . 36 kg . The batch size for the 
through mechanical generation of kinetic energy , not by the compounder used in this study is 3 to 4 kg ; however , due to 
addition of external heat , and therefore molten processing material cost , a much smaller batch size was used . The drug 
can be achieved below the T , or Tm of the polymeric 55 and polymer powders were accurately weighed , premixed in 
materials . The process does not involve large - scale flow of a bag , and loaded into the feed conduit as a blended powder . 
molten material , and therefore overloading the drive motor The compounder is operated by a digital control system 
as a result of high polymer melt viscosity is not a significant which allows the operating parameters , i . e . , revolutions per 
problem as with HME . These attributes of TKC provide minute ( RPM ) and ejection temperature , to be set prior to the 
substantial benefits over HME for pharmaceutical manufac - 60 compounding operation . A temperature analyzer measures 
turing applications . the average temperature inside the compounder vessel and in 
TKC offers all of the same advantages of HME with this case with small batch size , the temperature output was 
respect to pharmaceutical manufacturing , e . g . , non - solvent 20 to 40° C . lower than the skin temperature of the processed 
processing , providing intimate mixing of materials in the material owing to greater void volume in the vessel . The 
molten state , and highly efficient , scalable manufacturing . 65 TKC machine can be run in automatic mode in which the 
However , TKC has some very unique characteristics that digital control system ejects the material once the set tem 
may offer additional benefits to pharmaceutical manufactur - perature is reached within the vessel . For this study , material 
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( °C . ) 15 
66 . 1 
ejection was manually controlled and the temperature at the rate of 10° C . / min from 5 to 215° C . with a modulation 
moment of ejection was recorded from the digital output . temperature amplitude of 0 . 5° C . and a modulation period of 
The skin temperature of the material was measured imme 40 seconds for all studies . For the IND and KTZ dispersions 
diately following compounding using a Fluke 61 IR ther - in EUDRAGIT® L 100 - 55 the samples were analyzed by 
mometer ( Everett , Wash . ) . The operating parameters and 5 conventional , non - modulated DSC at a ramp rate of 10° 
skin temperatures of each compounded batch presented in C . / min from 5 to 200° C . Ultrahigh purity nitrogen was used this study are provided in Table 1 . as the purge gas at a flow rate of 40 mL / min . All data 
analyses were performed using TA Universal Analysis 2000 
TABLE 1 software . The thermogram for amorphous KTZ used in the 
Operating parameters of the thermokinetic compounding DSC analysis of the solid dispersions formulations of KTZ 
process for each processed batch . in MethocelTM E50 and Kollidon® 30 was obtained on a 
second heating of crystalline KTZ following an initial 
Eject Skin 
Temperature * Temperature heating to 215° C . followed by rapid cooling ( 20° C . / min ) to 
Composition RPM ( C . ) 5° C . The thermograms of MethocelTM E50 and Kollidon® 
30 were obtained by first run DSC following preheating of ACM : EUDRAGIT ® L100 - 55 1950 88 - 93 
( 1 : 2 ) the polymer powders to 90° C . for 15 minutes in an MF - 50 
KTZ : Methocel TM E50 ( 1 : 2 ) 2000 95 . 6 150 model moisture analyzer ( AND Company Ltd . Encino , 
KTZ : Kollidon ® 30 ( 1 : 2 ) 2000 77 . 2 140 - 150 Calif . ) to expel absorbed moisture . 
KTZ : EUDRAGIT ®L100 - 55 ( 1 : 2 ) 1600 71 . 1 125 
KTZ : EUDRAGIT ®L100 - 55 ( 1 : 4 ) 1600 71 . 1 20 Dissolution Testing . Dissolution testing of the TKC pro 90 
IND : EUDRAGIT ®L100 - 55 ( 1 : 2 ) 1950 68 . 3 140 cessed KTZ / MethocelTM E50 and KTZ / Kollidon® 30 for 
IND : EUDRAGIT ®L100 - 55 ( 1 : 4 ) 1600 < 65 . 6 60 mulations was performed according to USP 29 Apparatus 2 
guidelines ( paddle method ) at 50 rpm in a Vankel 7000 * Eject temperature was measured by R sensor as an average over the entire vessel volume . 
The eject temperature was lower than the actual product temperature due to the small batch Dissolution Tester ( Vankel Technology Group , Cary , N . C . ) 
size . 25 equipped with a model VK 8000 auto sampler . The medium 
HPLC Analysis . All HPLC analysis presented in this ( 900 mL pH 6 . 8 phosphate buffer ) was degassed prior to use 
study was conducted using a Waters ( Milford , Mass . ) high and maintained at 37 + 0 . 5° C . during testing . An amount of performance liquid chromatography ( HPLC ) system each tested formulation equivalent to 100 mg KTZ ( ~ 18 equipped with a photodiode array detector ( Model 996 ) , and times saturation solubility ) was added to each dissolution an auto sampler ( Model 717 Plus ) . The chromatographic 30 vessel ( n = 3 ) . Aliquots of the dissolution media ( 5 mL ) were data were collected and integrated using Empower® Version sampled at 10 , 20 , 30 , 60 , 120 , 180 , 240 , 360 , and 1 , 440 5 . 0 software . The column used was a Phenomenex® Luna 5 minutes . All aliquots of dissolution media were filtered um C18 ( 2 ) 100 A , 150 mmx4 . 6 mm ( Phenomenex® , Tor using Acrodisc® CR 13 mm syringe filters with a 0 . 2 um rance , Calif . ) . The mobile phase for ACM consisted of 15 : 85 
( v / v ) acetonitrile : deionized water . The retention time of 35 PTFE membrane ( Pall Life Sciences , East Hills , N . Y . ) . 
ACM was approximately 3 . 5 min with a flow rate of 1 Filtered aliquots were then diluted in a 1 : 1 ratio with the 
mL / min . Chromatograms were extracted at 244 nm . For KTZ HPLC mobile phase ( described above ) . Sampled ali 
KTZ , the mobile phase consisted of 50 : 50 ( v / v ) acetonirtile : quots of dissolution media were analyzed for drug content 
pH 6 . 8 phosphate buffer . The retention time of KTZ was by the KTZ HPLC method described previously . Area under 
approximately 6 . 1 min at a flow rate of 1 . 2 mL / min . Chro - 40 the dissolution curve ( AUDC ) was calculated using the 
matograms were extracted at 225 nm . linear trapezoidal method . 
Hot - Melt Extrusion ( HME ) . The hot - melt extruded com - Analysis of Drug Degradation in TKC Processed Com 
positions presented in the DSC analysis of the KTZ : Metho - positions . To investigate the aggressive nature of the TKC 
celTM E50 ( 1 : 2 ) and KTZ : Kollidon® ( 1 : 2 ) TKC processed process and its effect on the chemical stability of drug 
samples were produced with a HAAKE Minilab II Micro 45 molecules , HPLC was performed on TKC processed com 
Compounder ( Thermo Electron Corporation , Newington , positions of ACM : EUDRAGIT® L 100 - 55 ( 1 : 2 ) and KTZ : 
N . H . ) equipped with twin , co - rotating conical screws ( 5 / 14 Kollidon® 30 ( 1 : 2 ) to identify any significant degradation of 
mm diameter ) . All powder blends were fed into the extruder these drug molecules which may have occurred during 
barrel via the Minilab manual feeding device . No external processing . For this analysis , six independent samples of the 
dye was applied at the outlet of the extruder barrel , and 50 TKC processed ACM and KTZ compositions were evalu 
therefore extruded materials were forced through the 1 . 0x ated by HPLC and compared to a pure drug standard . The 
4 . 0 mm rectangular outlet port . The operating parameters for results of this analysis for the ACM : EUDRAGIT® L 100 - 55 
both compositions presented were 170° C . and 300 RPM . ( 1 : 2 ) formulations are shown in FIG . 1 . Since each of the 
After processing the extrudates were ground in a blade chromatograms obtained by HPLC analysis of the TKC 
grinder ( Capresso Inc . , Closter , N . J . ) for 2 minutes . The 55 material was identical , only a single representative chro 
resulting ground product was then passed over a 60 mesh matogram is provided in FIG . 1 . It is seen in this figure that 
sieve . The material which passed through the sieve was the representative chromatogram of the TKC processed 
manually milled in a porcelain mortar and pestle for 1 min samples is identical to the ACM standard . A single , well 
to yield a fine powder . DSC analysis was then conducted on defined peak with a retention time of 3 . 54 minutes repre 
this finely milled powder . 60 senting the elution of ACM from the column is seen in the 
Differential Scanning calorimetry ( DSC ) . DSC analysis chromatogram representing the TKC processed samples . 
was conducted using a TA Instruments Model 2920 DSC Each sample injection was evaluated for 8 minutes ; how 
( New Castle , Del . ) equipped with a refrigerated cooling ever , the reported figures were truncated at about 4 minutes 
system . Samples were weighed to 15 + 5 mg in aluminum as there were no absorption peaks beyond the primary ACM 
crimped pans ( Kit 0219 - 0041 , Perkin - Elmer Instruments , 65 peak . Degradation of ACM would be identified by the 
Norwalk , Conn . ) . For the KTZ dispersions in MethocelTM appearance of additional peaks to the primary ACM standard 
E50 and Kollidon® 30 the samples were heated at a ramp peak or by changes in the retention time or shape of the 
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ACM peak . Since neither of these was observed , it was DSC analysis of the HME processed KTZ : MethocelTM 
concluded that no significant degradation of ACM occurred E50 ( 1 : 2 ) sample revealed that a much more heterogeneous 
during TKC processing . dispersion was produced by HME than TKC . Two distinct 
A similar result for the KTZ : Kollidon® 30 ( 1 : 2 ) compo - low - temperature transitions are seen at approximately 40° C . 
sition is presented in FIG . 2 . The representative chromato - 5 and 66° C . which may indicate the presence of amorphous 
gram of the TKC processed samples shown in this figure is domains of KTZ ( 40° C . ) as well as domains of molecularly 
identical to the KTZ standard with the exception of a single dispersed KTZ in MethocelTM E50 ( 66° C . ) . Also , what 
peak eluting at about 1 . 2 minutes . This secondary peak is the appears to be an exotherm ( peak at ~ 145º C . ) followed by 
result of the Kollidon® 30 polymer as can be seen by the an endotherm ( minimum at ~ 150 ) may represent further 
polymer peak shown in the last row of FIG . 2 . A well - 10 phase separation of a small amount of KTZ from the 
defined peak with a retention time of about 6 . 1 minutes polymer matrix during the DSC experiment . 
representing the elution of KTZ from the column is seen in In summary , the results of this DSC analysis demonstrate 
the chromatogram representing the TKC processed samples . that a completely amorphous dispersion of KTZ domains in 
Each sample injection was evaluated for 10 minutes ; how - MethocelTM E50 was produced by TKC processing with 
ever , the reported figures were truncated at about 6 . 5 min - 15 similar dispersion properties as those reported by previous 
utes as there were no absorption peaks beyond the primary researchers for similar systems produced by HME . Addi 
KTZ peak . Since no large unknown peaks or any apparent tionally , it was revealed that a more homogenously dispersed 
changes in the primary KTZ peak were observed by chro system was achieved with TKC processing than with HME 
matographic analysis , it was concluded that degradation of processing . 
KTZ did not result from TKC processing . 20 The TKC processing time of the KTZ : Kollidon® 30 ( 1 : 2 ) 
DSC Analysis of TKC Processed Compositions with formulation was approximately 10 seconds and skin tem 
Thermally Stable Polymers . With the aim of demonstrating peratures of the molten material were measured in the range 
the application of TKC for the production of amorphous of 140 to 150° C . As before , the processed materials 
solid dispersion formulations , KTZ was processed with two experienced temperatures near the melting point of KTZ 
thermally stable polymers , MethocelTM E50 and Kollidon® 25 only for a very brief duration . Upon exit from the com 
30 . Immediately following processing the KTZ : MethocelTM pounder the KTZ : Kollidon® 30 ( 1 : 2 ) formulation had the 
E50 composition had the appearance of a large agglomer - appearance of a uniform molten mass , white to yellow in 
ated mass with a skin temperature of 150° C . ( as determined color . DSC analysis was conducted on this TKC processed 
by IR thermometer and a rubber - like consistency . The skin composite as well as the Kollidon® 30 unprocessed polymer 
temperature of the compounded product at the moment of 30 and amorphous KTZ to determine the morphology and the 
exit ( 150° C . ) is a good indication that the compounded dispersed state of KTZ in the polymer . Also , a KTZ : 
materials did not experience temperatures more than a few Kollidon® 30 ( 1 : 2 ) HME processed composition ( 170° 
degrees above the melting point of KTZ ( 151° C . ) during C . / 300 RPM ) was included in the analysis for a comparative 
processing . Moreover , the processing time was approxi evaluation of the two processes . The results of DSC analysis 
mately 10 seconds and since the material temperature 35 are presented in FIG . 4 . 
increases with processing time , the compounded mass only Similarly to MethocelTM , the Kollidon® 30 polymer has 
momentarily experienced elevated temperatures . a very subtle thermal transition with only a gradual down 
DSC analysis was conducted on the KTZ : MethocelTM ward slope indicating a steady increase in heat capacity of 
E50 ( 1 : 2 ) TKC processed composition to determine the the polymer with increasing temperature . A very slight 
morphology of KTZ in the composite as well its dispersed 40 increase in downward slope appears in the 150 to 160° C . 
state in the polymer . The MethocelTM E50 unprocessed temperature range followed by a short plateau which may 
polymer , amorphous KTZ , and a KTZ : MethocelTM E50 ( 1 : 2 ) indicate the completion of the polymer ' s molten transition . 
HME processed composition ( 170° C . / 300 RPM ) were also Again , the glass transition of amorphous KTZ is shown in 
included in the analysis for comparison . It can be seen in this figure at 45° C . to enable comparison with the T s of the 
FIG . 3 that MethocelTM E50 is a completely amorphous 45 TKC and HME processed samples . The thermograms of 
polymer with a very slight molten transition that appears to TKC and HME processed KTZ : Kollidon® 30 ( 1 : 2 ) compo 
begin at about 140° C . This transition is very subtle and the sitions show the same general characteristics , i . e . , they both 
sample size constraint of the utilized DSC system precludes demonstrate complete amorphousness of KTZ with a broad 
adequate resolution of this event ( 41 ) . Amorphous KTZ is T . ranging between 50 and 80° C . The greater To of the 
seen in this figure to have a To of approximately 45° C . The 50 KTZ : Kollidon® composite than that of amorphous KTZ 
absence of thermal events indicating recrystallization or demonstrates the miscibility of the drug in the polymer as 
melting reveals the stability of the amorphous state of KTZ . their intermolecular interactions lead to plasticization of 
The TKC processed KTZ : MethocelTM E50 ( 1 : 2 ) composi Kollidon® while having the opposite effect on amorphous 
tion appears to be a single phase system as indicated by the KTZ . Comparing this result to the previous KTZ : Metho 
single broad To with midpoint at about 45° C . ; however , the 55 celTM E50 composition , it is clear that KTZ is substantially 
equivalence of this T , to that of amorphous KTZ suggests more miscible with povidone than with hypromellose . 
that this transition is the result of amorphous domains of Although the thermograms of the TKC and HME pro 
KTZ distributed in the MethocelTM E50 matrix . If a molecu cessed KTZ : Kollidon® 30 ( 1 : 2 ) compositions appear simi 
lar dispersion of KTZ in MethocelTM E50 were achieved , the lar , closer evaluation reveals a difference in the distribution 
To of the composite would be expected to lie between the T . 60 of KTZ in the polymer . The calculated midpoints of the 
of KTZ and that of the polymer . The broadening of the KTŽ broad T s observed with both the TKC and HME processed 
T , is the result of mixing interactions between the amor - samples were 61° C . and 67° C . , respectively . The lower 
phous drug domains and the polymer on heating during the midpoint of the TKC processed sample indicates regions of 
DSC experiment . A similar distribution of itraconazole the analyzed sample that are more rich in KTZ content 
( ITZ ) in hypromellose after HME processing was reported 65 which causes the T , to shift downward toward that of pure 
by Six et al . in which the composition contained separate amorphous KTZ . The TKC processed sample also shows an 
drug and polymer - rich phases ( 41 ) . obvious secondary thermal transition with onset near 160° 
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C . that may indicate a polymer rich region of the sample . with Kollidon® owing to the presence of free hydroxyl 
Such a transition is not as apparent with the HME processed groups ( hydrogen bonding sies ) on MethocelTM which sta 
composition . Considering these events together , it appears bilize ITZ in solution . Since KTZ is also a weak base and 
that the TKC processed KTZ : Kollidon® 30 ( 1 : 2 ) formula molecularly very similar to ITZ , this mechanism of stabili 
tion is somewhat heterogeneous in comparison to the HME 5 zation is likely the cause for the discrepancy in supersatu 
sample as there appears to be drug rich and polymer rich ration observed between the two formulations investigated regions within a very small sample of the processed mass . in this study . Correlating these in vitro results to the in vivo 
This result may be attributable to the size and aggressiveness counterpart indicates that greater supersaturation of KTZ in of the TKC machine utilized in this study . The TKC machine the intestinal tract and hence greater absorption would be used in this study is designed for aggressive compounding to 10 achieved with the MethocelTM E50 formulation over the compatibilize dissimilar waste plastics by imparting high Kollidon ® 30 formulation . These results thus indicate the frictional and shear forces on the materials . The capabilities 
of this particular machine with respect to melt compounding potential impact of TKC with regard to improving oral drug therapies with poorly water - soluble drugs . therefore far exceed the requirements of this study . There 
fore , the machine was operated at very low RPM relative to 15 Production of Solid Dispersion Systems by TKC with a 
normal operation and run times were extremely brief . Addi Thermolabile Polymeric Carrier . As discussed previously , 
tionally , as mentioned before the batch size used in the study TKC has the capability of processing polymers in their 
was 2 to 3 times lower than the ideal batch . All of these molten states below their rigid - to - molten transition tempera 
factors result in a non - ideal mixing profile within the tures . It was also discussed above that a substantial limita 
machine which likely contributed to the two phase compo - 20 tion of HME processing is the required use of additives 
sition seen with the KTZ : Kollidon® 30 ( 1 : 2 ) formulation . when thermal degradation and / or molten flow restricts pro 
Microscopic heterogeneity was not detected by DSC analy cessing . Therefore , it was the aim of this study to demon 
sis for the MethocelTM formulation because molecular mix strate the use of TKC to produce amorphous solid dispersion 
ing that would produce a Toshift was not achieved with this systems of KTZ and indomethacin ( IND ) in the thermolabile 
composition . Homogenous mixing of KTZ and Kollidon® 25 polymer EUDRAGIT® L 100 - 55 without the use of pro 
30 would be improved by increasing processing time ; how - cessing agents such as plasticizers or thermal lubricants . The 
ever , given the aggressive nature of the TKC machine successful production of these compositions demonstrates a 
utilized in this study more ideal processing times of 20 to 30 substantial benefit of TKC processing over HME process 
seconds were not possible as they would lead to polymer ing . 
degradation . The future development of TKC for pharma - 30 Two batches of KTZ : EUDRAGIT® L 100 - 55 with dif 
ceutical applications will involve the modification of the fering drug : polymer ratios ( 1 : 2 ) and ( 1 : 4 ) , were processed 
machine design to allow for modulation of the aggressive - by TKC . The texture of the material upon exiting the 
ness of compounding to accommodate a number of different compounder was similar to the previously described 
pharmaceutical applications and to allow for longer process samples , i . e . rubbery agglomerated mass . The skin tempera 
ing times to ensure composite homogeneity . 35 ture of the two compounded batches was measured to be 
Dissolution Testing of TKC Processed KTZ in METHO - 125° C . and 90° C . for the KTZ : EUDRAGIT® L 100 - 55 
CELTM E50 and KOLLIDON® 30 . Supersaturation disso - ( 1 : 2 ) and ( 1 : 4 ) batches , respectively . These temperatures are 
lution testing in pH 6 . 8 phosphate buffer was conducted on significant because they are below the T of EUDRAGIT® 
the KTZ : MethocelTM E50 ( 1 : 2 ) and KTZ : Kollidon® 30 L 100 - 55 ( 127° C . ) , below the melting point of KTZ ( 151° 
( 1 : 2 ) TKC processed samples to evaluate the extent of KTZ 40 C . ) , and below the onset of degradation of EUDRAGIT® L 
supersaturation achieved with these two formulations . The 100 - 55 ( ~ 150° C . ) ( 43 ) . As before , processing times were 
results of this study are presented in FIG . 5 . The concen - brief ( ~ 10 seconds ) and the processed materials were only 
tration of KTZ in solution at each time point was normalized momentarily exposed to elevated temperatures . Again , the 
by the saturation solubility of KTZ in neutral pH media size and aggressiveness of the compounder used in this 
( 5 . 98 ug / mL ( 42 ) in order to provide a more direct repre - 45 study limited control of the energy imparted on the com 
sentation of supersaturation . In FIG . 5 it can be seen that the pounded materials , and as a result portions of the processed 
KTZ : MethocelTM E50 ( 1 : 2 ) and KTZ : Kollidon® 30 ( 1 : 2 ) batches showed obvious signs of polymer degradation . 
formulations exhibit rapid dissolution rates , reaching 87 % However , there were also large portions of the processed 
and 82 % of their respective maximum concentrations in the batches which showed no signs of degradation and these 
first 10 minutes . However , the KTZ : MethocelTM E50 ( 1 : 2 ) 50 portions were collected for further analysis . A smaller scale 
formulation produced much more extensive supersaturation machine with more flexible operating parameters will be 
as indicated by a maximum C / Ceg value of 7 . 6 , as compared used in future studies in order to provide more precise 
to the KTZ : Kollidon® 30 ( 1 : 2 ) formulation which showed process control so as to minimize intrabatch variations . 
a maximum C / Co , value of only 1 . 4 . The duration of In FIG . 6 , the DSC thermograms of both KTZ : 
supersaturation with the KTZ : MethocelTM E50 ( 1 : 2 ) formu - 55 EUDRAGIT® L 100 - 55 TKC processed batches are shown 
lation was also found to far exceed that of the KTZ : along with the unprocessed polymer , drug : polymer simple 
Kollidon® 30 ( 1 : 2 ) formulation as indicated by their respec mixtures , and bulk KTZ for comparison . The thermogram 
tive 24 hour C / Ceg values of 4 . 9 and 1 . 2 , respectively . The for the KTZ : EUDRAGIT® L 100 - 55 ( 1 : 4 ) batch demon 
total area under the dissolution curve ( AUDC ) for the strates that KTZ in this formulation was rendered entirely 
KTZ : MethocelTM E50 ( 1 : 2 ) and KTZ : Kollidon® 30 ( 1 : 2 ) 60 amorphous by TKC processing as indicated by the absence 
formulations were determined to be 852 and 177 ug . hr / mL , of the melting endotherm for crystalline KTZ at approxi 
respectively . These AUDC values are a clear indication of mately 151° C . as seen in the corresponding simple mixture . 
the superior stabilization of supersaturated concentrations of Avery slight amount of crystalline KTZ was detected in the 
KTZ provided by MethocelTM E50 over Kollidon® 30 . The KTZ : EUDRAGIT® L 100 - 55 ( 1 : 2 ) batch as indicated by the 
same result was achieved with supersaturated concentrations 65 very shallow and broad endotherm occurring in the same 
of itraconazole ( ITZ ) . This was attributed to stronger inter - range as the melting event of crystalline KTZ in the simple 
molecular interactions between ITZ and MethocelTM than mixture . Although slight crystallinity was detected for this 
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batch , the composition represents a substantial reduction in tions from thermally incompatible materials , e . g . high melt 
the crystallinity of KTZ as compared to the corresponding ing point drugs with thermolabile polymers . As most poorly 
simple mixture . water - soluble drugs have high melting temperatures , the 
Both KTZ : EUDRAGIT® L 100 - 55 batches were pro application of TKC processing for the production of amor 
cessed substantially below the melting point of KTZ , yet 5 phous solid dispersion systems will allow for greater flex 
TKC processing was able to transform the drug from its ibility in formulation as thermolabile polymers such as 
native crystalline structure into an amorphous form . More - EUDRAGITR L 100 - 55 can be utilized as carriers without 
over , the dispersion of KTZ into EUDRAGIT® L 100 - 55 the need for processing aids . Additionally , by eliminating the 
was achieved without the use of plasticizers or other pro - need for processing agents such as plasticizers and / or ther 
cessing agents . Previously , it was found that the addition of 10 mal lubricants , TKC processing can be utilized to produce 
20 % triethyl citrate was required to successfully process an more stable solid dispersion formulations and formulations 
ITZ : EUDRAGIT® L 100 - 55 ( 1 : 2 ) formulation due to tem - with drug release characteristics that are not influenced by 
perature restrictions and the excessive melt viscosity of additives . Therefore , by enabling molten processing at tem 
unplasticized EUDRAGIT® L 100 - 55 . A disadvantage of peratures below the melting points and glass transition 
the presence of large amounts of plasticizers in a solid 15 temperatures of both the carrier and active materials , TKC 
dispersion system is that it can reduce the stability of the processing represents a substantial advancement in manu 
system and alter drug release profiles . Hence , the capability facturing technology for solid dispersion systems . 
of TKC to produce an amorphous composition from ther 
mally incompatible materials ( a high melting point drug and Example 2 
a thermolabile polymer ) without the use of processing aids 20 
indicates a substantial advantage of TKC over HME for the A further study provides a demonstration that amorphous 
production of amorphous solid dispersion systems . solid dispersions of poorly water soluble drugs can be 
Compositions of IND in EUDRAGIT® L100 - 55 were produced using a novel high energy manufacturing technol 
also processed by TKC to study the effect with a different ogy , thermokinetic compounding ( TKC ) , having equivalent 
drug molecule . The melting point of IND is 161° C . and 25 properties to compositions produced by hot melt extrusion 
therefore the production of amorphous dispersions of IND ( HME ) with substantially reduced processing times . 
with EUDRAGIT® L100 - 55 by thermal methods is also Solid dispersions of poorly water soluble drugs , itracon 
restricted by the aforementioned problems of polymer deg - azole ( ITZ ) and griseofulvin ( GRIS ) , in hydrophilic carriers 
radation . As with the previous KTZ formulations , two IND ( 1 : 2 drug : carrier ratio ) , hydroxypropyl methylcellulose and 
batches were processed in drug to polymer ratios of ( 1 : 4 ) 30 polyvinylpyrollidone , were produced using a novel high 
and ( 1 : 2 ) . Both products exited the compounder as molten energy manufacturing process and compared to equivalent 
agglomerated masses with a slight yellow color . The skin formulations processed by HME . Modulated differential 
temperatures of the IND : EUDRAGIT® L100 - 55 ( 1 : 4 ) and scanning calorimetry ( mDSC ) and X - ray diffraction ( XRD ) 
( 1 : 2 ) batches were 60 and 140° C . , respectively . were used to assess the amorphous nature of the composi 
The thermograms for the IND : EUDRAGIT® L100 - 55 35 tions . Supersaturated dissolution testing was conducted by 
batches are shown in FIG . 7 along with unprocessed adding an amount of drug equivalent to 10 - times equilib 
EUDRAGIT® L100 - 55 polymer , simple mixtures , and bulk rium solubility to evaluate the degree and extent of super 
IND for comparison . It is seen in this figure that both TKC saturation . Potency testing was performed by dissolving a 
processed batches contain IND in a substantially amorphous known quantity of drug product in a suitable solvent and 
form . The IND : EUDRAGIT® L100 - 55 ( 1 : 4 ) batch appears 40 measuring the concentration of drug substance . Assay and 
to have slightly greater crystalline drug content than the dissolution samples were analyzed by HPLC . 
IND : EUDRAGIT® L100 - 55 ( 1 : 4 ) batch which is evident by Supersaturated dissolution testing was performed based 
the sharper melting endotherm at approximately 161° C . on the USP XXIX apparatus II dissolution test using a VK 
This can be attributed to the difference in processing con 7010 dissolution apparatus ( Varian , Inc . , Palo Alto , Calif . ) 
ditions between the two batches ; i . e . reduced RPM ( 1600 vs . 45 and VK 8000 autosampler ( Varian , Inc . , Palo Alto , Calif . ) . 
1950 ) and lower skin temperature ( 60° C . vs . 140° C . ) for An equivalent amount of 10x0 . 1N HCl media equilibrium 
the 1 : 4 versus the 1 : 2 batch . However , despite processing at solubility was weighed and added to the dissolution vessel 
much “ colder ” conditions , the drug content of the IND : containing 900 mL of 0 . 1N HCl media . During testing 5 mL 
EUDRAGIT® L100 - 55 ( 1 : 4 ) batch was rendered substan - samples were removed from the dissolution vessels without 
tially amorphous by TKC processing . In both cases , the 50 replacement after 5 , 10 , 15 , 30 , 45 and 60 min . Samples were 
temperature of the material was substantially lower than the immediately filtered , diluted in a 1 : 1 ratio with mobile 
melting point of IND indicating that an amorphous disper - phase , vortexed mixed and transferred into 1 mL vials 
sion of IND in EUDRAGIT® L 100 - 55 can be produced by ( VWR International , West Chester , Pa . ) for analysis . 
TKC below the drug ' s melting point without the use of Griseofulvin dissolution samples were analyzed using a 
processing aids . 55 Waters ( Waters Corporation , Milford , Mass . ) high perfor 
The slight crystallinity observed with these two IND : mance liquid chromatography ( HPLC ) system consisting of 
EUDRAGIT® L100 - 55 batches again can be attributed to dual Waters 515 Syringe Pumps , a Waters 717 Autosampler 
the use of the large compounder with the relatively small and a Waters 996 Photo Diode Array extracting at a wave 
batch sizes . Precise control is required to render the polymer length of 293 . 4 nm . The system was operated under isocratic 
molten and the drug amorphous without degrading 60 flow at 1 mL / min using a mobile phase consisting of 60 : 35 : 5 
EUDRAGIT® L100 - 55 . However , such control is not pos - water : acetonitrile : tetrahydrofuran equipped with a Phenom 
sible with the large compounder and thus the batches were enex Luna CN 100 A , 250 mmx4 . 6 mm ( Phenomenex® , 
processed conservatively so as not to degrade the polymer . Torrance , Calif . ) HPLC column . Data were collected and 
The result of conservative operation of the compounder was analyzed using Empower® Version 5 . 0 software . 
slight IND crystallinity in both processed batches . 65 Supersaturated dissolution testing results for griseofulvin : 
In summary , the results of this study demonstrate the PVP prepared by TKC and by HME are shown in FIG . 8 . 
capability of TKC processing to form amorphous composi - The compositions exhibited substantially faster dissolution 
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rates than unprocessed drug substance . Furthermore , TKC phous compositions had significantly higher dissolution 
processed compositions exhibited the ability to supersatu rates than the crystalline drug substance , indicating potential 
rate media , offering the potential for enhanced bioavailabil for improved bioavailability . 
ity . Thus , TKC processed material exhibited similar physical 
pXRD testing was conducted using a Philips Model 1710 5 and chemical properties compared to compositions pro 
X - ray diffractometer ( Philips Electronic Instruments Inc . , duced by HME , and were produced with significantly 
Mahwah , N . J . ) . Samples of powder were placed into chan - shorter processing times . These results indicate that TKC is 
neled stages and the diffraction profile was measured from an effective and efficient method for producing pharmaceu 
5° to 50° using a 20 step size of 0 . 05° and dwell time of 3 tically acceptable solid dispersions , offering substantially 
s . The results of pXRD testing of griseofulvin : PVP K30 10 higher throughput than traditional HME processes . 
processed by TKC and by HME are shown in FIG . 9 . Results 
for the mixture and for griseofulvin in powder form are also Example 3 
shown for comparison . 
PXRD testing is used to evaluate the crystal structure of The inventors have also demonstrated that solid disper 
a material . Unprocessed griseofulvin exhibits several char - 15 sions of itraconazole ( ITZ ) and Eudragit® L100 - 55 can be 
acteristic peaks indicative of its crystallinity , which are also produced using a fusion process without the aid of a plas 
present in physical mixtures of griseofulvin and PVP . These ticizer to achieve superior solid state characteristics com 
peak are absent in compositions of griseofulvin and PVP pared to material produced using traditional manufacturing 
processed by TKC and HME , indicating that material pro techniques . 
cessed in both forms is amorphous . 20 In this study , solid dispersions of ITZ and Eudragit® 
Modulated Differential scanning calorimetry testing for L100 - 55 ( 1 : 2 ) were produced using TKC and compared to 
the griseofulvin products was performed using a TA Instru equivalent formulations processed by hot melt extrusion 
ments Model 2920 DSC ( New Castle , Del . ) and analyzed ( HME ) . HME processed material could not be produced 
using TA Universal Analysis 2000 Software . Samples were without the aid of a plasticizer . Triethyl citrate ( TEC ) was 
accurately weighed to 15 + 2 mg in aluminum crimped pans . 25 used as a plasticizer at 20 % w / w of dry polymer . Modulated 
Testing was performed at a ramp rate of 10° C . / min from 5 differential scanning calorimetry ( mDSC ) and X - ray diffrac 
to 275° C . using a modulation temperature amplitude of 0 . 5º tion ( XRD ) were used to assess the amorphous nature of the 
C . and a modulation period of 40 s under nitrogen purge at compositions . Supersaturated dissolution testing was con 
a flow rate of 40 mL / min . Drug free compositions were ducted based on the USP Method A enteric test by adding an 
heated a minimum of 50 C above the glass transition 30 amount of drug equivalent to 10 - times acid phase equilib 
temperature . rium solubility to evaluate the degree and extent of super 
Using mDSC testing it is possible to assess crystallinity Saturation . Potency testing was performed by dissolving a 
and glass transition of a composition . The results of mDSC known quantity of drug product in a suitable solvent . 
testing are shown in FIG . 10 . Examination of the heat flow Potency and dissolution samples were analyzed by HPLC . 
profile shows that griseofulvin exhibits a melting endotherm 35 Supersaturated dissolution testing of itraconazole : HPMC 
at 222° C . Formation of an amorphous composition formed E5 processed by TKC and by HME was performed based on 
by a quench cool of the 1st run sample , exhibits a charac - the USP XXIX apparatus II dissolution test using a VK 7010 
teristic griseofulvin glass transition temperature at 90° C . dissolution apparatus ( Varian , Inc . , Palo Alto , Calif . ) and VK 
Later down stream events associated with recrystallization 8000 autosampler ( Varian , Inc . , Palo Alto , Calif . ) . An 
and melting can also be seen in the thermogram . Heat flow 40 equivalent amount of 10x0 . 1N HCl media equilibrium solu 
profiles for the PVP K30 composition , as well as for bility was weighed and added to the dissolution vessel 
griseofulvin : PVP K30 compositions , do not exhibit melting containing 900 mL of 0 . 1N HC1 media . During testing 5 mL 
endotherms , confirming the amorphous results seen in samples were removed from the dissolution vessels without 
pXRD testing . Reversing heat flow profiles were examined replacement after 5 , 10 , 15 , 30 , 45 and 60 min . Samples were 
to determine material glass transition values . PVP K30 45 immediately filtered , diluted in a 1 : 1 ratio with mobile 
compositions exhibited a glass transition temperature of phase , vortexed mixed and transferred into 1 mL vials 
180° C . , while the amorphous griseofulvin glass transition ( VWR International , West Chester , Pa . ) for analysis . 
value was confirmed at 90° C . Compositions of griseofulvin : Dissolution samples were analyzed using a Waters ( Wa 
PVP K30 processed by both HME and TKC exhibited only ters Corporation , Milford , Mass . ) high performance liquid 
a single glass transition phase at approximately 1270 - 130° 50 chromatography ( HPLC ) system consisting of dual Waters 
C . , indicating that both compositions existed as only a single 515 Syringe Pumps , a Waters 717 Autosampler and a Waters 
phase . 996 Photo Diode Array extracting at a wavelength of 263 
Thus , solid dispersions prepared by TKC exhibited pro - nm . The system was operated under isocratic flow at 1 
cessing times under one minute , while processing of equiva mL / min using a mobile phase consisting of 70 : 30 : 0 . 05 
lent HME compositions required run times in excess of ten 55 acetonitrile : water : diethanolamine equipped with a Phenom 
minutes . XRD testing of the solid dispersions produced by enex Luna 5 mcm C18 ( 2 ) 100 A , 150 mmx4 . 6 mm ( Phe 
both TKC and HME showed an absence of crystalline peaks nomenex® , Torrance , Calif . ) HPLC column . Data were 
in the diffraction pattern , indicating an amorphous compo - collected and analyzed using Empower® Version 5 . 0 soft 
sition . mDSC testing of all compositions demonstrated the ware . 
absence of drug substance melting endotherms , supporting 60 Dissolution testing results are shown in FIG . 11 . Itracon 
the amorphous nature of the drug products . Furthermore , azole : HPMC solid dispersions produced by TKC and HME 
only a single glass transition temperature for TKC processed exhibited significantly higher dissolution rates with the 
was observed for the composition indicating that the mate capability of supersaturating . Additionally , no statistically 
rial was dispersed at a molecular level . Solid dispersions of significant difference was observed between manufacturing 
ITZ and GRIS produced by TKC also exhibited excellent 65 processes . This indicates that compositions produced by 
product potencies , with values ranging from 95 . 0 % - 105 . 0 % HME or TKC should provide equivalent bioavailabilities in 
of theoretical . Dissolution testing results showed that amor vivo . 
32 
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XRD testing of the itraconazole : HPMC E5 processed by 5 . 0 software . The results of the itraconazole : L100 - 55 
TKC and by HME was conducted using a Philips Model samples are shown in FIG . 14 . 
1710 X - ray diffractometer ( Philips Electronic Instruments Itraconazole is a weakly basic drug , having a higher 
Inc . , Mahwah , N . J . ) . Samples of powder were placed into solubility in acidic media relative neutral media , it is still 
channeled stages and the diffraction profile was measured 5 consider a poorly water soluble drug . Previous research has 
from 50 to 50° using a 20 step size of 0 . 05° and dwell time shown that pH change supersaturation test is the most 
of 3 s . Result of the XRD testing is shown in FIG . 12 . representative in vitro test to assess compositional perfor 
XRD testing is used to evaluate the crystal structure of a mance in vivo . Supersaturated dissolution testing is used to evaluate the dissolution rate and magnitude of supersatura material . Unprocessed itraconazole exhibits several charac 
teristic peaks indicative of its crystallinity . These peak are 10 tion achieved by an amorphous composition . Testing results showed that both compositions exhibited similar overall absent in compositions of itraconazole and HPMC processed dissolution profiles , with a longer tmax observed for TKC by TKC and HME , indicating that material processed in both processed material . Although slightly slower release rates forms is amorphous . were observed from TKC processed materials , a longer Modulated Differential scanning calorimetry testing of 15 ng 01 15 duration of greater extent of supersaturation was also 
itraconazole : HPMC E5 processed by TKC and by HME was observed indicating a potential for this composition to 
performed using a TA Instruments Model 2920 DSC ( New provide enhanced bioavailability . These performance differ 
Castle , Del . ) and analyzed using TA Universal Analysis ences may be due to the absence of plasticizer in TKC 
2000 Software . Samples were accurately weighed to 1512 processed material . 
mg in aluminum crimped pans . Testing was performed at a 20 Assessment of precipitation rates in vitro can be calcu 
ramp rate of 10° C . / min from 5 to 215° C . using a modu - lated by evaluation of the Supersaturated dissolution profile 
lation temperature amplitude of 0 . 5º C . and a modulation by identifying the maximum concentration achieved ( Cmax ) 
period of 40 s under nitrogen purge at a flow rate of 40 and performing a logarithmic transform on the data . The 
mL / min . Drug free compositions were heated a minimum of slope of the transformed data is correlated with the decay 
50° C . above the glass transition temperature . The results are 25 half life , with smaller calculated k values corresponding to 
shown in FIG . 13 . longer supersaturated half life times . Results from the data 
Examination of the heat flow profile was use to evaluate analysis ( FIG . 15 ) show that the composition produced by 
the crystallinity of the compositions . Itraconazole exhibits a TKC yielded a longer supersaturated solution half life 
characteristic melting endotherm at 171° C . , which was not compared to HME produced compositions ( 131 min vs 44 
present in the amorphous material . Additionally , this melting 30 min ) , which was attributed to the absence of plasticizer in 
endotherm was absent in all processed compositions , sup - the formulation . This performance could potentially result in 
porting the amorphous nature observed by pXRD analysis . higher bioavailabilities in vivo . 
Reversing heat flow profiles were examined to determine the XRD testing of itraconzaole : L100 - 55 processed by TKC 
glass transition temperature of the compositions . ITZ : was conducted using a Philips Model 1710 X - ray diffrac 
HPMC E5 compositions produced by HME and TKC both 35 tometer ( Philips Electronic Instruments Inc . , Mahwah , N . J . ) . 
exhibited a glass transition temperature of approximately Samples of powder were placed into channeled stages and 
115° C . tested , supporting an equivalent level of drug the diffraction profile was measured from 50 to 50° using a 
dispersion within the composition . 20 step size of 0 . 05° and dwell time of 3 s . The results are 
Itraconazole : L100 - 55 processed by TKC and HME were shown in FIG . 16 . 
also tested . Supersaturated dissolution testing was per - 40 XRD testing is used to evaluate the crystal structure of a 
formed based on the USP XXIX method A enteric dissolu - material . Unprocessed itraconazole exhibits several charac 
tion test using a VK 7010 dissolution apparatus ( Varian , Inc . , teristic peaks indicative of its crystallinity . These peak are 
Palo Alto , Calif . ) and VK 8000 autosampler ( Varian , Inc . , absent in compositions of itraconazole and L100 - 55 pro 
Palo Alto , Calif . ) . An equivalent amount of 10x0 . 1N HC1 cessed by TKC indicating that material processed in both 
media equilibrium solubility was weighed and added to the 45 forms is amorphous . 
dissolution vessel containing 750 mL of 0 . 1N HC1 media . Modulated Differential scanning calorimetry testing for 
After two hours , 250 mL of 0 . 2M Na PO , solution was the itraconazole : L100 - 55 processed by TKC was performed 
added to the dissolution vessel to achieve a pH of approxi - and compared to itraconazole : L100 - 55 with added plasti 
mately 6 . 8 . During testing 5 mL samples were removed from cizer ( TEC ) processed by HME . The tested were conducted 
the dissolution vessels without replacement after 120 , 125 , 50 on a TA Instruments Model 2920 DSC ( New Castle , Del . ) 
130 , 135 , 150 , 180 and 240 min . Samples were immediately and analyzed using TA Universal Analysis 2000 Software . 
filtered , diluted in a 1 : 1 ratio with mobile phase , vortexed Samples were accurately weighed to 15 + 2 mg in aluminum 
mixed and transferred into 1 mL vials ( VWR International , crimped pans . Testing was performed at a ramp rate of 10° 
West Chester , Pa . ) for analysis . C . / min from 5 to 215° C . using a modulation temperature 
Dissolution samples were analyzed using a Waters ( Wa - 55 amplitude of 0 . 5º C . and a modulation period of 40 s under 
ters Corporation , Milford , Mass . ) high performance liquid nitrogen purge at a flow rate of 40 mL / min . Drug free 
chromatography ( HPLC ) system consisting of dual Waters compositions were heated a minimum of 50° C . above the 
515 Syringe Pumps , a Waters 717 Autosampler and a Waters glass transition temperature . The results are shown in FIG . 
996 Photo Diode Array extracting at a wavelength of 263 17 . 
nm . The system was operated under isocratic flow at 1 60 Examination of reversing heat flow profiles can be used to 
mL / min using a mobile phase consisting of 70 : 30 : 0 . 05 assess the glass transition temperature of a composition . 
acetonitrile : water : diethanolamine equipped with a Phenom - Results showed that the glass transition temperature of 
enex Luna 5 mcm C18 ( 2 ) 100 Å , 150 mmx4 . 6 mm ( Phe - L100 - 55 was 127° C . , corresponding well with previously 
nomenex® , Torrance , Calif . ) HPLC column . Samples col - published results . Plasticization at 20 % w / w TEC reduces 
lected in the 0 . 1N HC1 media and neutralized media were 65 the temperature to 63° C . Compositions processed by HME 
injected in volumes of 200 mL respectively during testing . containing TEC exhibited a glass transition temperature of 
Data were collected and analyzed using Empower® Version 53° C . while compositions processed by TKC without the 
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plasticizer exhibited glass transition temperatures of 101°C . TABLE 3 
This difference in glass transition temperature is extremely 
Degradation Products for TKC Processed Materials . beneficial for providing enhanced long term stability of an 
amorphous composition . Hydrocortisone , TKC Processed 
This example demonstrates that solid dispersions of ITZ : 5 Description USP Material 
L100 - 55 were successfully produced using TKC , with Impurity - 3 . 2 0 . 20 % observed processing times under one minute and potencies Impurity - 3 . 9 0 . 26 % 0 . 27 % 
within + 5 % of target . XRD testing of TKC processed Impurity - 4 . 9 0 . 20 % 0 . 20 % 
0 . 62 % material exhibited an amorphous profile which was con Impurity - 5 . 5 0 . 64 % Deg . Product - 7 . 8 0 . 05 % firmed by the absence of crystalline drug melting endo Impurity - 8 . 7 0 . 13 % 0 . 10 % 
therms in mDSC analysis . This , in combination with the 
single glass transition observed , indicated the amorphous Analytical testing results indicated only minor degrada solid solution nature of the composition . Glass transition tion formation , which shows that TKC processing has sur temperatures ( T ) were identified using mDSC . Composi 15 prisingly low API degradation during the process . For tions produced without plasticizer using the TKC process example , while there was no change in the levels of impu 
exhibited Tg values of 100 . 7° C . while HME compositions rities , at 7 . 8 minutes only 0 . 05 % degradation of hydrocor containing TEC yielded Tg values of 53 . 2° C . Supersatu tisone could be detected . This level of degradation is actu 
rated dissolution testing showed no statistically significant ally below the ICH Guidelines for reporting degradation 
difference between the maximum concentration achieved in 20 products ( 45 ) . Furthermore , mass balance testing showed 
vitro ( TKC : 15 . 4 + 0 . 8 ug / ml , HME : 17 . 1 + 5 . 5 ug / ml ) , while that the TKC processed compositions exhibited 100 . 6 % of 
compositions produced by TKC exhibited significantly theoretical potency , further revealing the ability of this 
reduced precipitation rates in neutral media . process to minimize API degradation during processing . 
In conclusion , compositions processed by TKC without These results show that TKC significantly reduces degrada 
the aid of a plasticizer exhibited higher Tg and reduced 25 tion levels of APIs during processing , for example because 
supersaturation precipitation rates in vitro , indicating that of shorter processing times , as compared to HME . As shown 
TKC processing can provide enhanced solid state properties in Repka et al . , HME resulted in significant degradation 
and the potential for improved bioavailability of advanced levels and product potencies that varied from approximately 
solid dispersion formulations compared to those produced 70 % to almost 94 % . Thus , TKC results in lower degradation 
using traditional processing techniques . 30 which means higher percentages of the API in composition products , and higher levels of product potency . 
Example 4 Example 5 
This study investigates the stability of a thermally 
unstable API in the TKC manufacturing process . Hydrocor 35 This study focused on ternary solid dispersions with 
tisone is a drug that has been shown to exhibit degradation improved mixing . Multicomponent solid dispersions of itra conazole , Eudragit® L100 - 55 and Carbomer 974P produced during thermal pharmaceutical processing . Since it was 
known that other thermal pharmaceutical processing tech by twin screw hot melt extrusion have been shown to exhibit two discrete phases attributed to the presence of a L100 - 55 niques could generate hydrocortisone compositions , e . g . , 
Repka et al . ( 44 ) , the aim of this study was to test whether 40 ? 40 dominated phase and a Carbomer dominated phase . Com 
TKC processing could also generate compositions with a positions of itraconazole , Eudragit® L100 - 55 and Carbomer 
thermally unstable API . The amount of hydrocortisone deg 974P were processed by twin screw extrusion and TKC with 
radation found in Repka et al . was shown to be proportional the solid state attributes of the composites characterized by modulated differential scanning calorimetry ( mDSC ) . Com to the duration of processing with HME . 
Pharmaceutical compositions of hydrocortisone were pre m 45 positions of itraconazole : Eudragit® L100 - 55 were pro cessed in a 1 : 2 ratio . Compositions containing Carbomer pared by TKC , having an ejection temperature of approxi 
mately 160° C . , and compared to the unprocessed drug were produced using a Carbomer polymer level of 20 % . For compositions processed by twin screw hot melt extrusion , substance to evaluate the formation of degradation products 20 % TEC was used as a plasticizer . induced by processing . The hydrocortisone formulation pro 
cessed by TKC is presented in Table 2 . 50 Testing was conducted by weighing an approximately 15 mg sample and heating from 5 to 215° C . at a ramp rate of 
10° C . / min and amplitude of 0 . 5º C . Total heat flow profiles TABLE 2 are presented in FIG . 18 for Carbomer 974P , itraconazole : 
Formulation for Processing of Thermally Labile Compositions . L100 - 55 composites processed by TKC and HME , and 
itraconazole : Eudragit® L100 - 55 : Carbomer 974P compos 
Material % w / w ites processed by TKC and HME . The results show a 
Hydrocortisone , USP significant difference in the relaxation temperature onset of 
( Spectrum Chemical ) the itraconazole : Eudragit® L100 - 55 : Carbomer 974P com 
Kollidon VA 64 ( BASF posite processed by TKC when compared to twin screw hot 
Corp . ) 60 melt extrusion . Reversing heat flow profiles for these com 
positions are presented in FIG . 19 . As shown in FIG . 19 , 
Analytical testing of the hydrocortisone formulation pro - Itraconazole : Eudragit® L100 - 55 : Carbomer 974P formula 
cessed by TKC was performed by HPLC using a Phenom tions processed by TKC exhibited a single phase while 
enex C18 column and mobile phase of 65 : 35 methanol : water compositions produced by twin screw hot melt extrusion 
at a flow rate of 1 ml /min . Degradation products were 65 exhibited two discrete phases which corresponded to a 
identified and are described in terms of their retention time Eudragit® L100 - 55 dominated phase and a Carbomer 974P 
under this method . The results are presented in Table 3 . dominated phase . 
10 
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This study shows that TKC achieves more intimate mix - It is contemplated that any embodiment discussed in this 
ing of API with pharmaceutically acceptable excipient ( s ) , as specification can be implemented with respect to any API , 
compared to HME . Thus , when HME generates a compo excipient , carrier method , kit , reagent , or composition of the 
sition with two or more glass transition temperatures , TKC present invention , and vice versa . Furthermore , composi 
may be able to generate a composition with a single glass 5 tions of the invention can be used to achieve methods of the 
transition temperature using the same combination of APIs invention . 
and excipients . TKC may also be able to adjust the release It will be understood that particular embodiments 
properties and stability of a composition comprising various described herein are shown by way of illustration and not as 
limitations of the invention . The principal features of this APIs and excipients , including known composition mix 
tures . Such a TKC processed composition will have a higher 10 invention can be employed in various embodiments without departing from the scope of the invention . Those skilled in single glass transition temperature than the lower of the two the art will recognize , or be able to ascertain using no more or more glass transition temperatures of the first composi than routine experimentation , numerous equivalents to the tion . This will result in a more stable composition , likely specific procedures described herein . Such equivalents are with a longer shelf life . Thus , pharmaceutical compositions 15 cal compositions 15 considered to be within the scope of this invention and are with poor shelf - life may be amenable to processing by TKC , covered by the claims . resulting in improved stability and shelf - life . All publications and patent applications mentioned in the 
specification are indicative of the level of skill of those Example 6 skilled in the art to which this invention pertains . All 
20 publications and patent applications are herein incorporated 
This Example is directed to the use of functional additives by reference to the same extent as if each individual publi 
for nanoconfinement . Polymer matrix - based nanocompos cation or patent application was specifically and individually 
ites offer the ability to modify properties of pharmaceutical indicated to be incorporated by reference . 
composition , e . g . , to effect the relaxation of materials , glass The use of the word “ a ” or “ an ” when used in conjunction 
transition temperatures , stability , drug release rates , mois - 25 with the term " comprising ” in the claims and / or the speci 
ture uptake , and the like . To study this potential application , fication may mean “ one , ” but it is also consistent with the 
Aerosil R972 , a hydrophobic fumed silica , was incorporated meaning of “ one or more , " " at least one , ” and “ one or more 
into a pharmaceutical composition of itraconazole and than one . ” The use of the term “ or ” in the claims is used to 
Eudragit® L100 - 55 prepared by TKC and compared to a mean " and / or ” unless explicitly indicated to refer to alter 
composition without the fumed silica . These compositions 30 natives only or the alternatives are mutually exclusive , 
were evaluated by mDSC to assess changes in glass transi - although the disclosure supports a definition that refers to 
tion . Testing was conducted by weighing an approximately only alternatives and " and / or . ” Throughout this application , 
15 mg sample and heating from 5 to 215° C . at a ramp rate the term “ about " is used to indicate that a value includes the 
of 10° C . / min and amplitude of 0 . 5° C . Total heat flow inherent variation of error for the device , the method being 
profiles , presented in FIG . 20 , show that the composition 35 employed to determine the value , or the variation that exists 
containing Aerosil R972 exhibited a weaker relaxation event among the study subjects . 
compared to the Aerosil R972 free composition . The com - As used in this specification and claim ( s ) , the words 
position containing Aerosil R972 also had a visible glass “ comprising ” ( and any form of comprising , such as “ com 
transition event . Reversing heat flow profiles , presented in prise ” and “ comprises ” ) , “ having ” ( and any form of having , 
FIG . 21 , clearly show a slight decrease in temperature for the 40 such as " have ” and “ has ” ) , “ including ” ( and any form of 
glass transition event . These results are in line with results including , such as “ includes ” and “ include ” ) or “ containing ” 
described in a review article by Paul and Robeson ( 46 ) , ( and any form of containing , such as " contains ” and “ con 
discussing changes in physical properties due to confine - tain " ) are inclusive or open - ended and do not exclude 
ment effects . additional , unrecited elements or method steps . 
The present disclosure thus establishes TKC as a novel 45 The term “ or combinations thereof ” as used herein refers 
and improved technology for producing pharmaceutical to all permutations and combinations of the listed items 
solid dispersion systems . As a solvent - free , efficient , scale preceding the term . For example , " A , B , C , or combinations 
able manufacturing process , TKC possesses many of the thereof ” is intended to include at least one of : A , B , C , AB , 
attributes which made HME a preferred pharmaceutical AC , BC , or ABC , and if order is important in a particular 
manufacturing process . With regard to producing amor - 50 context , also BA , CA , CB , CBA , BCA , ACB , BAC , or CAB . 
phous solid dispersion systems in thermally stable poly - Continuing with this example , expressly included are com 
meric carriers , this disclosure demonstrates the close simi - binations that contain repeats of one or more item or term , 
larity between the two processes . However , the unique such as BB , AAA , MB , BBC , AAABCCCC , CBBAAA , 
attributes of TKC , i . e . , very brief processing times , reduced CABABB , and so forth . The skilled artisan will understand 
processing temperatures , and no - flow molten processing , 55 that typically there is no limit on the number of items or 
distinguish TKC as a superior technology to HME , particu - terms in any combination , unless otherwise apparent from 
larly in regards to processing of thermolabile materials as the context . 
well as high T / Tm / melt viscosity materials . By successfully All of the compositions and / or methods disclosed and 
producing amorphous compositions of high melting point claimed herein can be made and executed without undue 
drugs in a thermolabile polymer without the use of process - 60 experimentation in light of the present disclosure . While the 
ing aids , this disclosure demonstrates TKC to be a consid compositions and methods of this invention have been 
erable advancement in solid dispersion manufacturing tech - described in terms of preferred embodiments , it will be 
nology . Although the disclosures is focused on the use of apparent to those of skill in the art that variations may be 
TKC for the production of amorphous solid dispersion applied to the compositions and / or methods and in the steps 
systems , it is believed that TKC , TKM , and all variations in 65 or in the sequence of steps of the method described herein 
between have numerous and diverse applications to phar - without departing from the concept , spirit and scope of the 
maceutical manufacturing . invention . All such similar substitutes and modifications 
m 
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apparent to those skilled in the art are deemed to be within 16 . Goldberg , A . H . , Gibaldi , M . , Kanig , J . L . Increasing 
the spirit , scope and concept of the invention as defined by dissolution rates and gastrointestinal absorption of drugs 
the appended claims . via solid solutions and eutectic mixtures II . Experimental 
evaluation of eutectic mixture : urea - acetaminophen sys 
REFERENCES 5 tem . Journal of Pharmaceutical Sciences 1966 ; 55 : 482 - 7 . 
17 . Goldberg , A . H . , Gibaldi , M . , Kanig , J . L . , Mayersohn , 
1 . Lipinski , C . A . Avoiding investment in doomed drugs , is M . Increasing dissolution rates and gastrointestinal 
poor solubility an industry wide problem ? Current Drug absorption of drugs via solid dispersion in eutectic mix 
Discovery 2001 : 17 - 9 . tures IV . Chloramphenicol - urea system . Journal of Phar 
2 . Lipinski , C . A . , Lombardo , F . , Dominy , B . W . , Feeney , P . 10 maceutical Sciences 1966 ; 55 : 581 - 3 . 
J . Experimental and computational approaches to estimate 18 . Chiou , W . L . , Riegelman , S . Preparation and dissolution 
solubility and permeability in drug discovery and devel - characteristics of several fast - release solid dispersions of 
opment settings . Advanced Drug Delivery Reviews 1997 ; griseofulvin . Journal of Pharmaceutical Sciences 1969 ; 
23 ( 1 - 3 ) : 3 - 25 . 58 : 1505 - 9 . 
3 . Lipinski , C . A . Poor Aqueous Solubility — an Industry 15 19 . Summers , M . P . , Enever , R . P . Preparation and properties 
Wide Problem in Drug Delivery . American Pharmaceuti of solid dispersion system containing citric acid and 
cal Review 2002 ; 5 : 82 - 5 . primidone . Journal of Pharmaceutical Sciences 1976 ; 
4 . Serajuddin , A . T . M . Solid Disperison of Poorly Water 65 : 1613 - 161 . 
Soluble Drugs : Early Promises , Subsequent Problems , 20 . Goldberg , A . H . , Gibaldi , M . , Kanig , J . L . Increasing 
and Recent Breakthroughs . Journal of Pharmaceutical 20 dissolution rates and gastrointestinal absorption of drugs 
Sciences 1999 ; 88 ( 10 ) : 1058 - 66 . via solid solutions and eutectic mixtures I . Theoretical 
5 . Noyes , A . A . , Whitney , W . R . The rate of dissolution of considerations and discussion of the literature . Journal of 
solid substances in their own solutions . Journal of the Pharmaceutical Sciences 1965 ; 54 : 1145 - 8 . 
American Chemical Society 1897 ; 19 : 930 - 4 . 21 . Repka , M . , Koleng , J . , Zhang , F . , McGinity , J . W . 
6 . Sinswat , P . , Gao , X . , Yacaman , M . J . , Williams lii , R . O . , 25 Hot - Melt Extrusion Technology . In : Swarbrick , J . , Boy 
Johnston , K . P . Stabilizer choice for rapid dissolving high l an , J . , eds . Encyclopedia of Phamaceutical Technology . 
potency itraconazole particles formed by evaporative pre - 2nd ed . New York : Marcel Dekker , Inc ; 2002 . 
cipitation into aqueous solution . International Journal of 22 . Aitken - Nichol , C . , Zhang , F . , McGinity , J . W . Hot Melt 
Pharmaceutics 2005 ; 302 ( 1 - 2 ) : 113 - 24 . Extrusion of Acrylic Films . Pharmaceutical Research 
7 . Brittain , H . G . , Grant , D . J . W . Effects of Polymorphism 30 1996 ; 13 ( 5 ) : 804 - 8 . 
and Solid - State Solvation on Solubility and Dissolution 23 . Zhang , F . , McGinity , J . W . Properties of Sustained 
Rate . In : Brittain , H . G . , ed . Polymorphism in Pharma - Release Tablets Prepared by Hot - Melt Extrusion . Phar 
ceutical Solids . Boca Raton , Fla . : Informa Health Care ; maceutical Development and Technology 1999 ; 4 ( 2 ) : 241 
1999 : 279 - 330 . 50 . 
8 . Chowdary , K . P . R . , Babu , K . V . V . S . Dissolution , 35 24 . Zhang , F . , McGinity , J . W . Properties of Hot - Melt 
bioavailability and ulcerogenic studies on solid disper Extruded Theophylline Tablets Containing Poly ( Vinyl 
sions of indomethacin in water - soluble cellulose poly - Acetate ) . Drug Development and Industrial Pharmacy 
mers . Drug Development and Industrial Pharmacy 1994 ; 2000 ; 26 ( 9 ) : 931 - 42 . 
20 ( 5 ) : 799 - 813 . 25 . Repka , M . A . , McGinity , J . W . Hot - melt extruded films 
9 . Chen , X . , Young , T . J . , Sarkari , M . , Williams , I . , Robert 40 for transmucosal & transdermal durg delivery applica 
O . , Johnston , K . P . Preparation of cyclosporine A nano tions . Drug Delivery Technology 2004 ; 4 ( 7 ) : 40 , 2 , 4 - 7 . 
particles by evaporative precipitation into aqueous solu - 26 . Rambali , B . , Verreck , G . , Baert , L . , Massart , D . L . 
tion . International Journal of Pharmaceutics 2002 ; 242 ( 1 Itraconazole Formulation Studies of the Melt - Extrusion 
2 ) : 3 - 14 . Process with Mixture Design . Drug Development and 
10 . Sekikawa , H . , Arita , T . , Nakano , M . Dissolution behav - 45 Industrial Pharmacy 2003 ; 29 ( 6 ) : 641 - 52 . 
iors and gastrointestinal absorption of phenytoin in phe - 27 . Hulsmann , S . , Backensfeld , T . , Keitel , S . , Bodmeier , R . 
nytoin - polyvinylpyrrolidine coprecipitate . Chemical and Melt extrusion an alternative method for enhancing the 
Pharmaceutical Bulletin 1978 ; 26 : 118 - 26 . dissolution rate of 17 [ beta ] - estradiol hemihydrate . Euro 
11 . Jung , J . - Y . , Yoo , S . D . , Lee , S . - H . , Kim , K . - H . , Yoon , pean Journal of Pharmaceutics and Biopharmaceutics 
D . - S . , Lee , K . - H . Enhanced solubility and dissolution rate 50 2000 ; 49 ( 3 ) : 237 - 42 . 
of itraconazole by a solid dispersion technique . Interna - 28 . de Brabander , C . , Vervaet , C . , Remon , J . P . Development 
tional Journal of Pharmaceutics 1999 ; 187 ( 2 ) : 209 - 18 . and evaluation of sustained release mini - matrices pre 
12 . Rogers , T . L . , Johnston , K . P . , Williams III , R . O . pared via hot melt extrusion . Journal of Controlled 
Solution - Based Particle Formation of Pharmaceutical Release 2003 ; 89 ( 2 ) : 235 - 47 . 
Powders by Supercritical or Compressed Fluid Co2 and 55 29 . Crowley , M . M . , Fredersdorf , A . , Schroeder , B . , Kucera , 
Cryogenic Spray - Freezing Technologies . Drug Develop S . , Prodduturi , S . , Repka , M . A . , McGinity , J . W . The 
ment and Industrial Pharmacy 2001 ; 27 ( 10 ) : 1003 - 15 . influence of guaifenesin and ketoprofen on the properties 
13 . Hu , J . , Johnston , K . P . , Williams III , R . O . Nanoparticle of hot - melt extruded polyethylene oxide films . European 
Engineering Processes for Enhancing the Dissolution Journal of Pharmaceutical Sciences 2004 ; 22 ( 5 ) : 409 - 18 . 
Rates of Poorly Water Soluble Drugs . Drug Development 60 30 . Six , K . , Leuner , C . , Dressman , J . , Verreck , G . , Peeters , 
and Industrial Pharmacy 2004 ; 30 ( 3 ) : 233 - 45 . J . , Blaton , N . , Augustijns , P . , Kinget , R . , Van den Mooter , 
14 . Leuner , C . , Dressman , J . Improving drug solubility for G . Thermal Properties of Hot - Stage Extrudates of Itra 
oral delivery using solid dispersions . European Journal of conazole and Eudragit E100 . Phase separation and poly 
Pharmaceutics and Biopharmaceutics 2000 ; 50 ( 1 ) : 47 - 60 . morphism . Journal of Thermal Analysis and calorimetry 
15 . Breitenbach , J . Melt extrusion : from process to drug 65 2002 ; 68 ( 2 ) : 591 - 601 . 
delivery technology . European Journal of Pharmaceutics 31 . Six , K . , Verreck , G . , Peeters , J . , Brewster , M . E . , Van den 
and Biopharmaceutics 2002 ; 54 ( 2 ) : 107 - 17 . Mooter , G . Increased physical stability and improved 
39 
US 10 , 022 , 385 B2 
40 
dissolution properties of itraconazole , a class II drug , by What is claimed is : 
solid dispersions that combine fast - and slow - dissolving 1 . A method of making a composite comprising : process 
polymers . Journal of Pharmaceutical Sciences 2004 ; ing one or more active pharmaceutical ingredients ( APIs ) 
93 ( 1 ) : 124 - 31 . having an immiscible crystalline or intermediate morphol 
32 . Verreck G . Six . K . Van den Mooter . G . Baert . L . 5 ogy with one or more pharmaceutically acceptable excipi 
ents by thermokinetic compounding , wherein the processing Peeters , J . , Brewster , M . E . Characterization of solid renders the API amorphous , and the amorphous character of dispersions of itraconazole and hydroxypropylmethylcel the API improves the miscibility of the API and the excipi 
lulose prepared by melt extrusion — part I . International ents and the dissolution rate of the composite as compared 
Journal of Pharmaceutics 2003 ; 251 ( 1 - 2 ) : 165 - 74 . into thermally processing the crystalline or intermediate mor 
33 . Forster , A . , Hempenstall , J . , Tucker , I . , Rades , T . Selec - phology API with the excipients by a process other than 
tion of excipients for melt extrusion with two poorly thermokinetic compounding . 
water - soluble drugs by solubility parameter calculation 2 . The method of claim 1 , wherein one or more pharma 
and thermal analysis . International Journal of Pharmaceu ceutically acceptable excipients is a polymer having a high 
tics 2001 ; 226 ( 1 - 2 ) : 147 - 61 . 15 melt viscosity . 
34 . Breitenbach , J . Melt extrusion can bring new benefits to 3 . The method of claim 2 , wherein the polymer is a 
HIV therapy : the example of Kaletra tablets . American cellulose derivative . 
Journal of Drug Delivery 2006 ; 4 ( 2 ) : 61 - 4 . 4 . The method of claim 3 , wherein the cellulose derivative 
35 . Top 200 Drugs for 2006 by Sales . Drugs . com . 2007 . is selected from the group consisting of methylcellulose , 
( Accessed Aug . 6 , 2007 , 2007 , at www . drugs . com / 20 ethylcellulose , hydroxymethylcellulose , hydroxyethylcellu 
top200 . html .) lose , hydroxypropylcellulose , hydroxybutylcellulose , 
36 . Dittgen , M . , Fricke , S . , Gerecke , H . , Osterwald , H . Hot hydroxyethyl methylcellulose , hydroxypropyl methylcellu 
spin mixing a new technology to manufacture solid lose , carboxymethylcellulose , hydroxypropyl methylcellu lose acetate succinate , cellulose acetate phthalate , cellulose dispersions . Part 1 : Testosterone . Pharmazie 1995 ; 50 ( 3 ) : 
225 - 6 . 25 acetate trimellate , hydroxypropyl methylcellulose phthalate , a and cellulose acetate butyrate . 37 . Hamaura , T . , Newton , M . N . Interaction between Water 5 . The method of claim 2 , wherein the polymer is selected and Poly ( vinylpyrrolidone ) Containing Polyethylene Gly from the group consisting of polyvinylpyrrolidones , poly 
col . Journal of Pharmaceutical Sciences 1999 ; 88 ( 11 ) : acrylates , polymethacrylates , polyvinyl alcohols , polyethyl 
1228 - 33 . 20 ene glycols , polyvinyl acetate polyvinylpyrrolidone copoly 
38 . Park , B . D . , Balatinecz , J . J . A comparison of compound mers , polyethylene oxides , dimethylaminoethyl 
ing processes for wood - fiber / thermoplastic composites . methacrylate - methacrylic acid ester copolymers , ethylacry 
Polymer Composites 1997 ; 18 ( 3 ) : 425 - 31 . late - methylmethacrylate copolymers , poly ( methacrylate 
39 . Gopakumar , T . , Page , D . J . Y . S . Compounding of ethylacrylate ) copolymers , poly ( methacrylate methylmeth 
nanocomposites by thermokinetic mixing . Journal of 35 acrylate ) copolymers , starches , pectins , polysaccharides , 
Applied Polymer Science 2005 ; 96 ( 5 ) : 1557 - 63 . gum arabic , guar gum , and xanthan gum . 
40 . Gopakumar , T . , Page , D . J . Y . S . Polypropylene / graphite 6 . The method of claim 1 , wherein one or more pharma 
nanocomposites by thermo - kinetic mixing . Polymer ceutically acceptable excipients is a crystalline or semi 
Engineering and Science 2004 ; 44 ( 6 ) : 1162 - 9 . crystalline pharmaceutically acceptable polymer . 
41 . Six , K . , Berghmans . H . , Leuner . C . . Dressman . J . . Vanan 7 . The method of claim 1 , wherein at least one API is 
Werde , K . , Mullens , J . , Benoist , L . , Thimon , M . , Meublat , thermally labile . 
L . , Verreck , G . , Peeters , J . , Brewster , M . , Van den Mooter , 8 . The method of claim 1 , wherein at least one API is 
G . Characterization of Solid Dispersions of Itraconazole ization of Solid Dispersions of Itraconazole po poorly water - soluble . 
and Hydroxypropylmethylcellulose Prepared by Melt 9 . The method of claim 1 , wherein the unprocessed API has a crystalline morphology . Extrusion , Part II . Pharmaceutical Research 2003 ; 20 ( 7 ) : 45 10 . The method of claim 1 , wherein the unprocessed API 1047 - 54 . has an intermediate morphology . 42 . Glomme , A . , März , J . , Dressman , J . Comparison of a 11 . The method of claim 1 , wherein the amorphous API miniaturized shake - flask solubility method with auto has at least about 94 % drug potency as compared to the 
mated potentiometric acid / base titrations and calculated unprocessed API having an immiscible crystalline or inter 
solubilities . Journal of Pharmaceutical Sciences 2005 ; mediate morphology 
94 ( 1 ) : 1 - 16 . 12 . The method of claim 1 , wherein the composite pro 
43 . Petereit , H . - U . , Weisbrod , W . Formulation and process cessed by thermokinetic compounding does not comprise a 
considerations affecting the stability of solid dosage forms side e st orms p rocessing agent . p . 
formulated with methacrylate copolymers . European se 13 . The method of claim 1 , wherein the composite pro 
Journal of Pharmaceutics and Biopharmaceutics 1999 ; cessed by thermokinetic compounding is a single phase , 
47 ( 1 ) : 15 - 25 . amorphous composite . 
44 . Repka , A . , Gerding , T . , Repka , S . , McGinity , J . Influence 14 . The method of claim 13 , wherein the composite is 
of plasticizers and drugs on the physical - mechanical formulated for immediate release , delayed release , con 
properties of hydroxypropylcellulose films prepared by 60 trolled release , or extended release . 
hot melt extrusion . Drug Development and Industrial nment and Industrial 15 . The method of claim 1 , wherein the composite pro 
Pharmacy 1999 ; 25 ( 5 ) : 625 - 33 . cessed by thermokinetic compounding is a single phase , 
45 . ICH Harmonised Tripartite Guideline , Impurities in New miscible composite . 
Drug Products Q3B ( R2 ) ; Current Step 4 version , dated 16 . The method of claim 15 , wherein the composite is 
Jun . 2 , 2006 . is formulated for immediate release , delayed release , con 65 
46 . Paul , D . R . , Robeson , L . M . Polymer nanotechnology : trolled release , or extended release . 
Nanocomposites . Polymer 2008 ; 49 : 3187 - 3204 . * * * * * 
162 . 9 
